Search Result

Results for "

E3 ligase-recruiting Moiety

" in MCE Product Catalog:

By Targets:	E1/E2/E3 Enzyme (17) E3 Ligase Ligand-Linker Conjugates (286) Ligands for E3 Ligase (57) Ligands for Target Protein for PROTAC (31) 5-HT Receptor (2) ADC Antibody (1) ADC Cytotoxin (7) ADC Linker (26) Amino Acid Derivatives (2) Androgen Receptor (5) Antibiotic (6) Antifolate (1) AP-1 (1) APC (1) Apoptosis (23) Aryl Hydrocarbon Receptor (1) Aurora Kinase (1) AUTACs (6) Autophagy (4) Bacterial (12) Bcl-2 Family (5) Bcr-Abl (3) Biochemical Assay Reagents (6) Btk (1) Carbonic Anhydrase (1) Caspase (1) CD19 (1) CDK (3) Cholinesterase (ChE) (3) DNA/RNA Synthesis (4) Dopamine Receptor (1) Drug-Linker Conjugates for ADC (4) EGFR (1) Endogenous Metabolite (27) Epigenetic Reader Domain (9) Estrogen Receptor/ERR (4) FAK (2) FKBP (8) Fluorescent Dye (11) Fungal (1) GABA Receptor (1) GCGR (1) HDAC (6) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (3) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (1) Integrin (1) Isotope-Labeled Compounds (2) Liposome (2) MDM-2/p53 (6) MEK (1) MicroRNA (9) Microtubule/Tubulin (3) Mitochondrial Metabolism (2) Molecular Glues (20) NF-κB (3) Parasite (4) PARP (3) PD-1/PD-L1 (1) PERK (1) Progesterone Receptor (1) PROTAC Linkers (74) PROTACs (50) Ras (2) Reactive Oxygen Species (3) RIP kinase (1) SARS-CoV (1) Sirtuin (1) SNIPERs (1) STAT (1) Target Protein Ligand-Linker Conjugates (9) TGF-beta/Smad (1) Virus Protease (1) β-catenin (5)
By Research Areas:	Cancer (561) Cardiovascular Disease (2) Endocrinology (1) Infection (16) Inflammation/Immunology (49) Metabolic Disease (11) Neurological Disease (11)

By Targets:

E1/E2/E3 Enzyme (17)

E3 Ligase Ligand-Linker Conjugates (286)

Ligands for E3 Ligase (57)

Ligands for Target Protein for PROTAC (31)

5-HT Receptor (2)

ADC Antibody (1)

ADC Cytotoxin (7)

ADC Linker (26)

Amino Acid Derivatives (2)

Androgen Receptor (5)

Antibiotic (6)

Antifolate (1)

AP-1 (1)

APC (1)

Apoptosis (23)

Aryl Hydrocarbon Receptor (1)

Aurora Kinase (1)

AUTACs (6)

Autophagy (4)

Bacterial (12)

Bcl-2 Family (5)

Bcr-Abl (3)

Biochemical Assay Reagents (6)

Btk (1)

Carbonic Anhydrase (1)

Caspase (1)

CD19 (1)

CDK (3)

Cholinesterase (ChE) (3)

DNA/RNA Synthesis (4)

Dopamine Receptor (1)

Drug-Linker Conjugates for ADC (4)

EGFR (1)

Endogenous Metabolite (27)

Epigenetic Reader Domain (9)

Estrogen Receptor/ERR (4)

FAK (2)

FKBP (8)

Fluorescent Dye (11)

Fungal (1)

GABA Receptor (1)

GCGR (1)

HDAC (6)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (3)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Influenza Virus (1)

Integrin (1)

Isotope-Labeled Compounds (2)

Liposome (2)

MDM-2/p53 (6)

MEK (1)

MicroRNA (9)

Microtubule/Tubulin (3)

Mitochondrial Metabolism (2)

Molecular Glues (20)

NF-κB (3)

Parasite (4)

PARP (3)

PD-1/PD-L1 (1)

PERK (1)

Progesterone Receptor (1)

PROTAC Linkers (74)

PROTACs (50)

Ras (2)

Reactive Oxygen Species (3)

RIP kinase (1)

SARS-CoV (1)

Sirtuin (1)

SNIPERs (1)

STAT (1)

Target Protein Ligand-Linker Conjugates (9)

TGF-beta/Smad (1)

Virus Protease (1)

β-catenin (5)

By Research Areas:

Cancer (561)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (16)

Inflammation/Immunology (49)

Metabolic Disease (11)

Neurological Disease (11)

680

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Ligands for E3 Ligase E3 Ligase Ligand-Linker Conjugates Ligands for Target Protein for PROTAC E1/E2/E3 Enzyme

Cat. No.	Product Name	Target	Research Areas

HY-128807

*E3 ligase* Ligand 10**	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 10 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 10 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-129653

*E3 ligase* Ligand 18**	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 18 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 18 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-128811

*E3 ligase* Ligand 14**	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 14 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 14 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-43961

*E3 ligase* Ligand 8**	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 8 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 8 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-128810

*E3 ligase* Ligand 13**	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 13 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 13 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-128806

*E3 ligase* Ligand 9**	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 9 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 9 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins.

HY-KT001

*E3 Ligase* Ligand-Linker Conjugate Kit**	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-Linker Conjugate Kit is a series of synthesized compounds that incorporate an E3 ligase ligand and a linker used in PROTAC technology.

HY-144983

E3 ligase Ligand 22
Ligands for E3 Ligase Cancer

E3 ligase Ligand 22 (compound 139) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.
HY-144980

E3 ligase Ligand 21
Ligands for E3 Ligase Cancer

E3 ligase Ligand 21 (compound 2) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.
HY-144985

E3 ligase Ligand 23
Ligands for E3 Ligase Cancer

E3 ligase Ligand 23 (compound 17-6) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.

*E3 ligase* Ligand 22**	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 22 (compound 139) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.

*E3 ligase* Ligand 21**	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 21 (compound 2) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.

*E3 ligase* Ligand 23**	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 23 (compound 17-6) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway.

HY-N8096

Raddeanoside R17 Pulchinenoside E3	Others	Inflammation/Immunology
Raddeanoside R17 (Pulchinenoside E3) is a saponin compound that can be isolated from the root of Pulsatilla koreana. Raddeanoside R17 shows anti-inflammatory effects.

HY-126458

Thalidomide-O-PEG2-propargyl E3 ligase Ligand-Linker Conjugates 32	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-PEG2-propargyl (E3 ligase Ligand-Linker Conjugates 32) is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-130270

AhR Ligand-Linker Conjugates 1 E3 ligase Ligand-Linker Conjugates 57	E3 Ligase Ligand-Linker Conjugates	Cancer
AhR Ligand-Linker Conjugates 1 (E3 Ligase Ligand-Linker Conjugates 57) incorporates an IAP ligand for the E3 ubiquitin ligase, and a SNIPER linker. AhR Ligand-Linker Conjugates 1 can be used to design SNIPER.

HY-125906

VHL Ligand-Linker Conjugates 15 E3 ligase Ligand-Linker Conjugates 56	E3 Ligase Ligand-Linker Conjugates	Cancer
VHL Ligand-Linker Conjugates 15 incorporates an VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VHL Ligand-Linker Conjugates 15 can be used to design PROTACs.

HY-130521

Pomalidomide-amido-PEG3-C2-NH2 Cereblon Ligand-Linker Conjugates 22; E3 ligase Ligand-Linker Conjugates 55	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 22) is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-128814

cIAP1 Ligand-Linker Conjugates 6 hydrochloride E3 ligase Ligand-Linker Conjugates 35 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 6 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 6 hydrochloride can be used to design SNIPERs.

HY-128822

cIAP1 Ligand-Linker Conjugates 13 E3 ligase Ligand-Linker Conjugates 43	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 13 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 13 can be used to design SNIPERs.

HY-128813A

cIAP1 Ligand-Linker Conjugates 15 hydrochloride E3 ligase Ligand-Linker Conjugates 34 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 15 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 hydrochloride can be used to design SNIPERs.

HY-128815

cIAP1 Ligand-Linker Conjugates 14 E3 ligase Ligand-Linker Conjugates 36	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 14 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 14 can be used to design SNIPERs.

HY-128816A

cIAP1 Ligand-Linker Conjugates 2 Hydrochloride E3 ligase Ligand-Linker Conjugates 37 Hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 2 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 2 Hydrochloride can be used to design SNIPERs.

HY-128820

cIAP1 Ligand-Linker Conjugates 1 E3 ligase Ligand-Linker Conjugates 41	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 1 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 1 can be used to design SNIPERs.

HY-128819

cIAP1 Ligand-Linker Conjugates 3 E3 ligase Ligand-Linker Conjugates 40	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 3 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 3 can be used to design SNIPERs.

HY-128826

cIAP1 Ligand-Linker Conjugates 10 E3 ligase Ligand-Linker Conjugates 47	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 10 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 10 can be used to design SNIPERs.

HY-128812A

cIAP1 Ligand-Linker Conjugates 11 Hydrochloride E3 ligase Ligand-Linker Conjugates 33 Hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 11 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 Hydrochloride can be used to design SNIPERs.

HY-128813

cIAP1 Ligand-Linker Conjugates 15 E3 ligase Ligand-Linker Conjugates 34	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 15 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 can be used to design SNIPERs.

HY-128824

cIAP1 Ligand-Linker Conjugates 9 E3 ligase Ligand-Linker Conjugates 45	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 9 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 9 can be used to design SNIPERs.

HY-128812

cIAP1 Ligand-Linker Conjugates 11 E3 ligase Ligand-Linker Conjugates 33	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 11 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 can be used to design SNIPERs.

HY-128817

cIAP1 Ligand-Linker Conjugates 12 E3 ligase Ligand-Linker Conjugates 38	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 12 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 12 can be used to design SNIPERs.

HY-128825

cIAP1 Ligand-Linker Conjugates 8 E3 ligase Ligand-Linker Conjugates 46	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 8 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 8 can be used to design SNIPERs.

HY-128823

cIAP1 Ligand-Linker Conjugates 7 E3 ligase Ligand-Linker Conjugates 44	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 7 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 7 can be used to design SNIPERs.

HY-128818

cIAP1 Ligand-Linker Conjugates 5 E3 ligase Ligand-Linker Conjugates 39	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 5 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 5 can be used to design SNIPERs.

HY-128821

cIAP1 Ligand-Linker Conjugates 4 E3 ligase Ligand-Linker Conjugates 42	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 4 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 4 can be used to design SNIPERs.

HY-128816

cIAP1 Ligand-Linker Conjugates 2 E3 ligase Ligand-Linker Conjugates 37	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 2 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 2 can be used to design SNIPERs.

HY-103612

Thalidomide-O-amido-C3-COOH Cereblon Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 15	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-21930

Pomalidomide-PEG4-C-COOH Cereblon Ligand -Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 1	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG4-C-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.

HY-115560

Thalidomide-O-amido-C3-NH2 Cereblon Ligand-Linker Conjugates 16; E3 ligase Ligand-Linker Conjugates 52	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-103615

Thalidomide-O-amido-C4-N3 Cereblon Ligand-Linker Conjugates 4; E3 ligase Ligand-Linker Conjugates 18	E3 Ligase Ligand-Linker Conjugates	Others
Thalidomide-O-amido-C4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-41549

Pomalidomide-PEG4-Ph-NH2 Cereblon Ligand-Linker Conjugates 9; E3 ligase Ligand-Linker Conjugates 2	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG4-Ph-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.

HY-112617

Thalidomide-O-amido-PEG2-C2-NH2 Cereblon Ligand-Linker Conjugates 10; E3 ligase Ligand-Linker Conjugates 24	E3 Ligase Ligand-Linker Conjugates	Cancer Inflammation/Immunology
Thalidomide-O-amido-PEG2-C2-NH2 incorporates an E3 ligase ligand and a linker, can be an immunomodulater for the research of cancer.

HY-128716

Pomalidomide-PEG3-C2-NH2 Cereblon Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 30	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-112599

Pomalidomide-PEG4-C2-NH2 Cereblon Ligand-Linker Conjugates 8; E3 ligase Ligand-Linker Conjugates 22	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.

HY-115560A

Thalidomide-O-amido-C3-NH2 TFA Cereblon Ligand-Linker Conjugates 16 TFA; E3 ligase Ligand-Linker Conjugates 52 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-C3-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-125884

Pomalidomide-amido-C4-amido-C6-NH-Boc Cereblon Ligand-Linker Conjugates 21; E3 ligase Ligand-Linker Conjugates 54	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amido-C4-amido-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-111824

VH032-thiol-C6-NH2 VHL Ligand-Linker Conjugates 14; E3 ligase Ligand-Linker Conjugates 29	E3 Ligase Ligand-Linker Conjugates	Cancer
VH032-thiol-C6-NH2 (VHL Ligand-Linker Conjugates 14) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.

HY-107439

Thalidomide-O-amido-C8-NH2 Cereblon Ligand-Linker Conjugates 2; E3 ligase Ligand-Linker Conjugates 20	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-107438

Thalidomide-O-amido-C4-NH2 Cereblon Ligand-Linker Conjugates 6; E3 ligase Ligand-Linker Conjugates 19	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-112618

Thalidomide-O-amido-C6-NH2 Cereblon Ligand-Linker Conjugates 11; E3 ligase Ligand-Linker Conjugates 25	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-C6-NH2 (Cereblon Ligand-Linker Conjugates 11), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-128716B

Pomalidomide-PEG3-C2-NH2 hydrochloride Cereblon Ligand-Linker Conjugates 5 hydrochloride; E3 ligase Ligand-Linker Conjugates 30 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 5) hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-112078

(S,R,S)-AHPC-Me VHL ligand 2; E3 ligase Ligand 1A	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM.

HY-103613

Thalidomide-O-amido-C4-NH2 TFA Cereblon Ligand-Linker Conjugates 6 TFA; E3 ligase Ligand-Linker Conjugates 19 TFA	E3 Ligase Ligand-Linker Conjugates	Others
Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-103614

Thalidomide-O-amido-C8-NH2 TFA Cereblon Ligand -Linker Conjugates 2 TFA; E3 ligase Ligand-Linker Conjugates 20 TFA	E3 Ligase Ligand-Linker Conjugates	Others
Thalidomide-O-amido-C8-NH2 TFA (Cereblon Ligand -Linker Conjugates 2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-42424

(S,R,S)-AHPC-Me hydrochloride VHL ligand 2 hydrochloride; E3 ligase Ligand 1	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM.

HY-42424A

(S,R,S)-AHPC-Me dihydrochloride VHL ligand 2 dihydrochloride; E3 ligase Ligand 1 dihydrochloride	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me dihydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM.

HY-125846

(S,R,S)-AHPC-PEG1-OTs VH032-PEG1-OTs; VHL Ligand-Linker Conjugates 2; E3 ligase Ligand-Linker Conjugates 51	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG1-OTs is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.

HY-112618A

Thalidomide-O-amido-C6-NH2 TFA Cereblon Ligand-Linker Conjugates 11 TFA; E3 ligase Ligand-Linker Conjugates 25 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-107440

Thalidomide-O-amido-PEG3-C2-NH2 Cereblon Ligand-Linker Conjugates 3 ; E3 ligase Ligand-Linker Conjugates 14	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-112617A

Thalidomide-O-amido-PEG2-C2-NH2 TFA Cereblon Ligand-Linker Conjugates 10 TFA; E3 ligase Ligand-Linker Conjugates 24 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer Inflammation/Immunology
Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-103611

Thalidomide-O-amido-PEG3-C2-NH2 TFA Cereblon Ligand-Linker Conjugates 3 TFA; E3 ligase Ligand-Linker Conjugates 14 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-125883

Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc Cereblon Ligand-Linker Conjugates 20; E3 ligase Ligand-Linker Conjugates 53	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-114176

(S,R,S)-AHPC-C4-NH2 hydrochloride VH032-C4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 28	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.

HY-128832

Nutlin-C1-amido-PEG4-C2-N3 MDM2 Ligand-Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 48	E3 Ligase Ligand-Linker Conjugates	Cancer
Nutlin-C1-amido-PEG4-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Nutlin 3 based MDM2 ligand and 4-unit PEG linker used in PROTAC technology.

HY-103599

(S,R,S)-AHPC-PEG2-N3 VH032-PEG2-N3; VHL Ligand-Linker Conjugates 6; E3 ligase Ligand-Linker Conjugates 13	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology.

HY-103604

(S,R,S)-AHPC-PEG4-NH2 hydrochloride VH032-PEG4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 4 hydrochloride; E3 ligase Ligand-Linker Conjugates 7	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.

HY-103601

(S,R,S)-AHPC-PEG4-N3 VH032-PEG4-N3; VHL Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 4	E3 Ligase Ligand-Linker Conjugates	Others
(S,R,S)-AHPC-PEG4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.

HY-103600

(S,R,S)-AHPC-PEG1-N3 VH032-PEG1-N3; VHL Ligand-Linker Conjugates 9; E3 ligase Ligand-Linker Conjugates 3	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.

HY-103598

(S,R,S)-AHPC-PEG3-N3 VH032-PEG3-N3; VHL Ligand-Linker Conjugates 8; E3 ligase Ligand-Linker Conjugates 12	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG3-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.

HY-103602

(S,R,S)-AHPC-PEG3-NH2 hydrochloride VH032-PEG3-NH2 hydrochloride; VHL Ligand-Linker Conjugates 1 hydrochloride; E3 ligase Ligand-Linker Conjugates 5	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.

HY-153178

HECT E3-IN-1	E1/E2/E3 Enzyme	Others
HECT E3-IN-1 (compound 3) is a HECT E3 ligase inhibitor. HECT E3-IN-1 (compound 3) disrupts Ub binding to the noncovalent Ub-binding site of Nedd4-1.

HY-103602A

(S,R,S)-AHPC-PEG3-NH2 VH032-PEG3-NH2; VHL Ligand-Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 5 Free Base	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.

HY-103604A

(S,R,S)-AHPC-PEG4-NH2 VH032-PEG4-NH2; VHL Ligand-Linker Conjugates 4 ; E3 ligase Ligand-Linker Conjugates 7 Free Base	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.

HY-130271

(S,R,S)-AHPC-PEG5-COOH VH032-PEG5-COOH; VHL Ligand-Linker Conjugates 16; E3 ligase Ligand-Linker Conjugates 58	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG5-COOH (VH032-PEG5-COOH) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 5-unit PEG linker used in PROTAC technology.

HY-128848

Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH Cereblon Ligand-Linker Conjugates 14; E3 ligase Ligand-Linker Conjugates 49	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-112600

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 Cereblon Ligand-Linker Conjugates 12; E3 ligase Ligand-Linker Conjugates 23	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-103603

(S,R,S)-AHPC-PEG2-NH2 hydrochloride VH032-PEG2-NH2 hydrochloride; VHL Ligand-Linker Conjugates 3 hydrochloride; E3 ligase Ligand-Linker Conjugates 6	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.

HY-112600A

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA Cereblon Ligand-Linker Conjugates 12 TFA; E3 ligase Ligand-Linker Conjugates 23 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-128716A

Pomalidomide-PEG3-C2-NH2 TFA Cereblon Ligand-Linker Conjugates 5 TFA; E3 ligase Ligand-Linker Conjugates 30 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 5 (TFA)) is a synthetic E3 ligase ligand-linker conjugate comprising a Pomalidomide (HY-10984)-based cereblon ligand and a 3-unit PEG linker. Pomalidomide-PEG3-C2-NH2 TFA can be used for the synthesis of PROTACs.

HY-125843

Pomalidomide-PEG1-C2-N3 Cereblon Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 50	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG1-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology. Pomalidomide-PEG1-C2-N3 can be used to design a selective CDK6 PROTAC degrader CP-10. CP-10 induces the degradation of CDK6 with an DC₅₀ of 2.1 nM.

HY-103603A

(S,R,S)-AHPC-PEG2-NH2 VH032-PEG2-NH2 ; VHL Ligand-Linker Conjugates 3 ; E3 ligase Ligand-Linker Conjugates 6 Free Base	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG2-NH2 (VH032-PEG2-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.

HY-103606

(S,R,S)-AHPC-PEG6-C4-Cl VH032-PEG6-C4-Cl; VHL Ligand-Linker Conjugates 10; E3 ligase Ligand-Linker Conjugates 9	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG6-C4-Cl is a conjugate of ligands for E3 and 25-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-PEG6-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker. (S,R,S)-AHPC-PEG6-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

HY-148834

Pomalidomide-piperazine
Ligands for E3 Ligase Others

Pomalidomide-piperazine is an active compound that can be used to synthesis the E3 ligand for PROTAC.

HY-103607

(S,R,S)-AHPC-PEG2-C4-Cl VH032-PEG2-C4-Cl; VHL Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 10	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG2-C4-Cl (VH032-PEG2-C4-Cl) is a conjugate of ligands for E3 and 13-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-PEG2-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and an alkyl/ether-based linker. (S,R,S)-AHPC-PEG2-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

HY-147192

(S,R,S)-AHPC-O-PEG1-propargyl
Ligands for E3 Ligase Cancer

(S,R,S)-AHPC-O-PEG1-propargyl (Compound 10b) is an E3 ligand for the synthesis of PROTAC.
HY-143346

CCW16
Others Cancer

CCW16 is the covalent ligand for the E3 ubiquitin ligase RNF4. CCW16 can be used in the synthesis of protein degraders.

HY-103605

(S,R,S)-AHPC-C6-PEG3-C4-Cl VH032-C6-PEG3-C4-Cl; VHL Ligand-Linker Conjugates 12; E3 ligase Ligand-Linker Conjugates 8	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C6-PEG3-C4-Cl (VH032-C6-PEG3-C4-Cl) is a conjugate of ligands for E3 and 20-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-C6-PEG3-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and an alkyl/ether-based linker. (S,R,S)-AHPC-C6-PEG3-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

HY-143715

Cereblon inhibitor 1	Ligands for E3 Ligase	Cancer
Cereblon inhibitor 1, an isoindoline derivative, is a cereblon E3 ubiquitin ligase modulating agent. Cereblon inhibitor 1 has?the?potential?for?cancer research.

HY-136156

Pomalidomide-PEG6-butyl iodide	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG6-butyl iodide is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology.

HY-153215

MEL24	Others	Cancer
MEL24 is an Mdm2 E3 ligase inhibitor that reduces cell survival and increases sensitivity to DNA damaging agents in a p53-dependent manner for in vitro antitumor studies.

HY-130991

K-Ras ligand-Linker Conjugate 6	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 6 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 6 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-133799

Pomalidomide-C7-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-C7-COOH is a synthesized *E3 ligase* cereblon ligand-linker conjugate**. Pomalidomide-C7-COOH is an intermediate for the synthesis of PROTAC BCL-XL degraders.

HY-44432

Navitoclax-piperazine ABT-263-piperazine	Bcl-2 Family Ligands for Target Protein for PROTAC	Cancer
Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604).

HY-149934

DCAF1 binder 1	Ligands for E3 Ligase	Cancer
DCAF1 binder 1 is a selective for the CRL4 DCAF1 E3 ligase complex. DCAF1 binder 1 is a ligands for E3 Ligase, involving in targeted protein degradation (TPD).

HY-129703B

Thalidomide-PEG2-C2-NH2 hydrochloride Thalidomide-NH-PEG2-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG2-C2-NH2 hydrochloride is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-129703

Thalidomide-PEG2-C2-NH2 Thalidomide-NH-PEG2-C2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG2-C2-NH2 is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-W062696

BC-1382	E1/E2/E3 Enzyme	Inflammation/Immunology
BC-1382 is a potent ubiquitin E3 ligase HECTD2 inhibitor that specificly disrupts the HECTD2/PIAS1 interaction (IC₅₀≈ 5 nM).Anti-inflammatory activity.

HY-129703A

Thalidomide-PEG2-C2-NH2 TFA Thalidomide-NH-PEG2-C2-NH2 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG2-C2-NH2 TFA is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-130798

(S,R,S)-AHPC-amido-C5-acid	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-amido-C5-acid incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-amido-C5-acid can be used to design XY028-133 (HY-129180).

HY-136772

Pomalidomide-PEG1-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Others
Pomalidomide-PEG1-NH2 hydrochloride is a crosslinker-E3 ligase ligand conjugate, consisting of an E3 ligase ligand pomalidomide and a PEGylated crosslinker with terminal amine for reactivity with a carboxyl group on the target ligand.

HY-138551A

(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-Me-C10-NH2 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-Me-C10-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC ligand, it can be used in PROTAC technology.

HY-130683

Lenalidomide-propargyl-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-propargyl-C2-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Lenalidomide-propargyl-C2-NH2 hydrochloride can be used to design the PROTAC MD-224 (HY-114312).

HY-148556

Thalidomide-O-C6-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C6-azide is a synthesized *E3 ligase* ligand-linker conjugate** (E3 Ligase Ligand-Linker Conjugates) that incorporates the Thalidomide (Thalidomide (HY-14658)) based cereblon ligand and a linker used in PROTAC technology.

HY-133699

Pomalidomide-PEG4-COOH	Ligands for E3 Ligase	Others
Pomalidomide-PEG4-COOH is a E3 ligase ligand-linker conjugate. Pomalidomide-PEG4-COOH contains the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology (extracted from patent WO2017184995A1).

HY-133484B

Thalidomide-PEG2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG2-NH2 hydrochloride is a synthesized *E3 ligase* ligand-linker conjugate** (E3 Ligase Ligand-Linker Conjugates) that incorporates the Thalidomide (Thalidomide (HY-14658)) based cereblon ligand and a linker used in PROTAC technology.

HY-132998

HDAC6 degrader-1	PROTACs	Others
HDAC6 degrader-1 is a PROTAC that comprises a selective HDAC6 inhibitor Nexturastat A (Nex A) as the HDAC6 binder, a linker and a ligand for recruiting E3 ligase. HDAC6 degrader-1 induces significant degradation of HDAC6, exhibits excellent selectivity against other HDACs, and demonstrates efficient inhibition of cell proliferation.

HY-139656

cIAP1 ligand 4
Ligands for E3 Ligase Cancer

cIAP1 ligand 4 is a ligand for E3 ligase that can be used in the synthesis of PROTACs.

HY-100507

Avadomide CC 122	E1/E2/E3 Enzyme Apoptosis Molecular Glues	Cancer Inflammation/Immunology
Avadomide (CC 122) is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity and induces apoptosis of diffuse large B-cell lymphoma (DLBCL) cell lines. Avadomide exhibits potent antitumor and immunomodulatory activities.

HY-130682

Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase and a linker. Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride can be used to design the PROTAC MD-224 (HY-114312).

HY-128808

cIAP1 ligand 1 E3 ligase Ligand 12	Ligands for E3 Ligase	Cancer
cIAP1 ligand 1 is the LCL161 derivative based IAP ligand. cIAP1 ligand 1 can be connected to the ABL ligand for protein by a linker to form SNIPER.

HY-128809

cIAP1 ligand 2 E3 ligase Ligand 11	Ligands for E3 Ligase	Cancer
cIAP1 ligand 2 is the LCL161 derivative based IAP ligand. cIAP1 ligand 2 can be connected to the ABL ligand for protein by a linker to form SNIPER.

HY-43722

Lenalidomide-Br	Ligands for E3 Ligase	Cancer
Lenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-Br can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC STAT3 degrader SD-36 (HY-129602).

HY-132288

Pom-8PEG	E3 Ligase Ligand-Linker Conjugates	Cancer
Pom-8PEG, an E3 ligase ligand-linker conjugate, incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase and an 8-unit PEG linker. Pom-8PEG can be used in the synthesis of PROTAC, such as IDO1 PROTAC degrader.

HY-128756

SIAIS178	PROTACs Bcr-Abl	Cancer
SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology with an IC₅₀ of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity.

HY-141797

MS33	Histone Methyltransferase PROTACs	Cancer
MS33 is a potent WDR5 degrader, with K_ds of 870 nM and 120 nM for VCB and WDR5, respectively. MS33 induces WDR5 degradation in an E3 ligase VHL, and proteasome-dependent manner. MS33 can be used for the research of acute myeloid leukemia.

HY-131189

N-Boc-SBP-0636457-OH	Ligands for E3 Ligase	Cancer
N-Boc-SBP-0636457-OH, a ligand for E3 ubiquitin ligase, is used in the recruitment of IAP E3 ligases. N-Boc-SBP-0636457-OH can be connected to the ligand for Bcl-xL by a linker to form PROTAC Bcl-xL degrader-1 (HY-131188).

HY-141448

NRX-2663	β-catenin	Cancer
NRX-2663 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF^β-TrCP. NRX-2663 enhances the binding of β-catenin peptide for β-TrCP with an EC₅₀ of 22.9 µM and a K_d of 54.8 nM.

HY-138550A

(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-PEG3-NH2 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-PEG3-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based ligand and 3-unit PEG linker used in PROTAC technology.

HY-141450

NRX-103095	β-catenin	Cancer
NRX-103095 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF^β-TrCP. NRX-103095 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC₅₀ of 163 nM.

HY-131295

PD0325901-O-C2-dioxolane	MEK Ligands for Target Protein for PROTAC	Cancer
PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader.

HY-130642

(S,R,S)-AHPC-Me-C10-Br	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-C10-Br is a synthesized *E3 ligase* ligand-linker conjugate*. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase* linker and MS432 based on the MEK1/2 inhibitor PD0325901.

HY-132938

(S,R,S)-AHPC-Me-decanedioic acid	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-decanedioic acid is an E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs.

HY-139655

cIAP1 Ligand-Linker Conjugates 16	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 16 is an E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs.

HY-133046

VHL Ligand-Linker Conjugates 17	E3 Ligase Ligand-Linker Conjugates	Cancer
VHL Ligand-Linker Conjugates 17 incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VHL Ligand-Linker Conjugates 17 can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 is a highly potent androgen receptor (AR) PROTAC degrader.

HY-130499

ERRα Ligand-Linker Conjugates 1	Target Protein Ligand-Linker Conjugates	Cancer
ERRα Ligand-Linker Conjugates 1 incorporates a ligand for estrogen-related receptor alpha (ERRα), and a PROTAC linker, which recruit E3 ligases MDM2. ERRα Ligand-Linker Conjugates 1 can be used in the synthesis of a series of PROTACs, such as PROTAC ERRalpha Degrader-1 (HY-128838). PROTAC ERRalpha Degrader-1 is an ERRα degrader.

HY-101291

Iberdomide CC-220	Ligands for E3 Ligase Apoptosis Molecular Glues	Inflammation/Immunology Cancer
Iberdomide (CC-220) is an orally active and potent *cereblon (CRBN) E3 ligase* modulator (CELMoD) with an IC₅₀** of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities.

HY-41547

Thalidomide 4-fluoride Cereblon ligand 4; E3 ligase Ligand 4	Ligands for E3 Ligase	Cancer
Thalidomide 4-fluoride (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1 (HY-129966).

HY-103597

Thalidomide-O-COOH Cereblon ligand 3; E3 ligase Ligand 3	Ligands for E3 Ligase	Others
Thalidomide-O-COOH (Cereblon ligand 3) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs.

HY-103596

Thalidomide-4-OH Cereblon ligand 2; E3 ligase Ligand 2	Ligands for E3 Ligase	Cancer
Thalidomide-4-OH (Cereblon ligand 2) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-4-OH (Cereblon ligand 2) can be connected to the ligand for protein by a linker to form PROTACs.

HY-128837

Nutlin carboxylic acid MDM2 ligand 1; E3 ligase Ligand 16	Ligands for E3 Ligase	Cancer
Nutlin carboxylic acid (MDM2 ligand 1) is the Nutlin 3-based MDM2 ligand. Nutlin carboxylic acid can be connected to the ligand for protein by a linker to form PROTAC.

HY-141449

NRX-103094	Molecular Glues β-catenin	Cancer
NRX-103094 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF^β-TrCP. NRX-103094 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC₅₀ of 62 nM and a K_d of 0.6 nM.

HY-152859

Brigimadlin
BI 907828
E1/E2/E3 Enzyme Cancer

Brigimadlin (BI 907828) is an E3 ubiquitin-protein ligase MDM-2 inhibitor. Brigimadlin serves as an antineoplastic agent.

HY-125905

VH032-cyclopropane-F VHL ligand 3; E3 ligase Ligand 19	Ligands for E3 Ligase	Cancer
VH032-cyclopropane-F is the VH032-based VHL ligand. VH032-cyclopropane-F can be connected to the ligand for protein (e.g., SMARCA BD ligand) by a linker to form PROTACs (e.g., PROTAC 1). PROTAC 1 is a partial degrader of SMARCA2 and SMARCA4.

HY-130815A

MAK683-CH2CH2COOH hydrochloride	Ligands for Target Protein for PROTAC Histone Methyltransferase	Cancer
MAK683-CH2CH2COOH binds to EED (embryonic ectoderm development protein). MAK683-CH2CH2COOH and a VHL ligand for the E3 ubiquitin ligase have been used to design PROTAC EED degrader-1 (HY-130614) and PROTAC EED degrader-2 (HY-130615).

HY-130815

MAK683-CH2CH2COOH	Histone Methyltransferase Ligands for Target Protein for PROTAC	Cancer
MAK683-CH2CH2COOH binds to EED (embryonic ectoderm development protein). MAK683-CH2CH2COOH and a VHL ligand for the E3 ubiquitin ligase have been used to design PROTAC EED degrader-1 (HY-130614) and PROTAC EED degrader-2 (HY-130615).

HY-148143

Pomalidomide-C6-NHS ester	E3 Ligase Ligand-Linker Conjugates	Others
Pomalidomide-C6-NHS ester is a synthesized E3 ligase ligand-linker conjugate, incorporating the Pomalidomide based cereblon ligand and NHS ester linker.

HY-132858

Thalidomide-4-O-C10-COOH
E3 Ligase Ligand-Linker Conjugates Cancer

Thalidomide-4-O-C10-COOH is a E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs.

HY-148142

Pomalidomide-C3-NHS ester	E3 Ligase Ligand-Linker Conjugates	Others
Pomalidomide-C3-NHS ester is a synthesized E3 ligase ligand-linker conjugate, incorporating the Pomalidomide based cereblon ligand and NHS ester linker.

HY-10984

Pomalidomide CC-4047	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

HY-139345

(S,R,S)-AHPC-CO-C9-acid VH032-NH-CO-C9-acid	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-CO-C9-acid is an E3 ligase ligand-linker conjugate that can be connected to the ligand for protein to form PROTACs.

HY-130295

Pomalidomide-PEG2-Tos
E3 Ligase Ligand-Linker Conjugates Cancer

Pomalidomide-PEG2-Tos is an E3 ligase ligand-linker conjugates, composed of a cereblon ligand and two-unit PEG linker.

HY-13296

PYR-41	E1/E2/E3 Enzyme Apoptosis	Cancer
PYR-41 is a selective and cell permeable inhibitor of ubiquitin-activating enzyme E1 with an IC₅₀ of < 10 μM, with little activity at E2 and E3.

HY-138783

Thalidomide-Piperazine-Piperidine	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Piperazine-Piperidine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-43723

PROTAC BET-binding moiety 2
Ligands for Target Protein for PROTAC Cancer

PROTAC BET-binding moiety 2 is an inhibitor of BET bromodomain.

HY-132939

2-(2,6-Dioxopiperidin-3-yl)phthalimidine-C5-Br	E3 Ligase Ligand-Linker Conjugates	Cancer
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-C5-Br is a E3 ligase ligand-linker conjugate for PROTAC.

HY-130640

(S,R,S)-AHPC-Me-C7 ester
E3 Ligase Ligand-Linker Conjugates Cancer

(S,R,S)-AHPC-Me-C7 ester is a E3 ligase ligand-linker conjugate used to synthesise BCL-X_L PROTAC degraders.

HY-123967

RNF5 inhibitor inh-02	E1/E2/E3 Enzyme	Inflammation/Immunology
RNF5 inhibitor inh-02 is a potent inhibitor of *E3 ubiquitin ligase* RNF5/RMA1. RNF5 inhibitor inh-02 leads to significant F508del-CFTR rescue (EC₅₀**=2.2 uM) in bronchial epithelial cells homozygous for the F508del mutation. RNF5 inhibitor inh-02 can be used for cystic fibrosis research.

HY-130822

K-Ras ligand-Linker Conjugate 4	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 4 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 4 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-130823

K-Ras ligand-Linker Conjugate 5	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 5 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 5 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-130707

K-Ras ligand-Linker Conjugate 3	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 3 (Compound 001371) incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 3 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-107442

*PROTAC BRD4-binding moiety* 1**	Epigenetic Reader Domain Ligands for Target Protein for PROTAC	Cancer
PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136).

HY-141010

Thalidomide-O-PEG4-amine	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-PEG4-amine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-140844

Thalidomide-O-PEG4-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-PEG4-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-141014

Thalidomide-O-PEG4-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-PEG4-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-131185

Pomalidomide-amido-C3-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-134983

Thalidomide-Piperazine 5-fluoride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Piperazine 5-fluoride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-111836

NRX-252114	Molecular Glues β-catenin	Cancer
NRX-252114 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF^β-TrCP. NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with an EC₅₀ of 6.5 nM and a K_d of 0.4 nM. NRX-252114 induces mutant β-catenin degradation.

HY-129610

KB02-SLF	PROTACs FKBP	Cancer
KB02-SLF is a PROTAC-based nuclear FKBP12 degrader (molecular glue). KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF.

HY-107451

PROTAC BET-binding moiety 1
Ligands for Target Protein for PROTAC Cancer

PROTAC BET-binding moiety 1 is a key intermediate for the synthesis of high-affinity BET inhibitors.

HY-130814

Thalidomide-NH-C4-NH2 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C4-NH2 TFA (compound 29c) is an E3 ligase ligand-linker conjugate, and incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-NH-C4-NH2 TFA is used in PROTAC BRD2/BRD4 degrader-1 (HY-130612). PROTAC BRD2/BRD4 degrader-1 is a potent and selective BET protein BRD4 and BRD2 degrader.

HY-138792

Glutarimide-Isoindolinone-NH-PEG2-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Glutarimide-Isoindolinone-NH-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand and a linker used in PROTAC technology.

HY-138783A

Thalidomide-Piperazine-Piperidine hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Piperazine-Piperidine hydrochloride is a synthesized E3 ligase ligand-linker conjugate. Thalidomide-Piperazine-Piperidine hydrochloride incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138773

Thalidomide-PEG5-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-131874

Thalidomide-O-C7-acid	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C7-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138790

Glutarimide-Isoindolinone-NH-PEG4-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Glutarimide-Isoindolinone-NH-PEG4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand and a linker used in PROTAC technology.

HY-141015

Pomalidomide-PEG4-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG4-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138775

Thalidomide-PEG3-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138774

Thalidomide-PEG4-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-128846A

Pomalidomide-C2-NH2 hydrochloride Cereblon Ligand-Linker Conjugates 15 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-131876

Thalidomide-O-C3-acid	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C3-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138860

Thalidomide-O-C11-acid	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C11-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-131880

Thalidomide-O-C2-acid	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C2-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-131889

Thalidomide-O-C5-acid	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C5-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138791

Glutarimide-Isoindolinone-NH-PEG3-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Glutarimide-Isoindolinone-NH-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand and a linker used in PROTAC technology.

HY-140055

Thalidomide-PEG4-Propargyl	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG4-Propargyl is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-143270

*PROTAC BRD9-binding moiety* 5**	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
PROTAC BRD9-binding moiety 5 is a selective BRD9 binder with an IC₅₀ value of 4.20 μM, can be used for the synthesis of PROTACs. PROTAC BRD9-binding moiety 5 has antiproliferative activity against cancer cells.

HY-138771

Thalidomide-NH-PEG3-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138782

Thalidomide-Piperazine-PEG1-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Piperazine-PEG1-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138778

Thalidomide-Propargyne-PEG1-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Propargyne-PEG1-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138776

Thalidomide-Propargyne-PEG3-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Propargyne-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-128846

Pomalidomide-C2-NH2 Cereblon Ligand-Linker Conjugates 15	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology.

HY-138780

Thalidomide-Piperazine-PEG3-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Piperazine-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-141010A

Thalidomide-O-PEG4-amine hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-PEG4-amine hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-130950

Thalidomide-O-C4-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138777

Thalidomide-Propargyne-PEG2-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Propargyne-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138772

Thalidomide-NH-PEG2-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-130951

Thalidomide-O-C6-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C6-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-141887

Thalidomide-O-C6-NHBoc	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C6-NHBoc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138781

Thalidomide-Piperazine-PEG2-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Piperazine-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-130269

β-Naphthoflavone-CH2-OH β-NF-CH2-OH	Ligands for E3 Ligase	Cancer
β-Naphthoflavone-CH2-OH (β-NF-CH2-OH) is a ligand for arylhydrocarbon receptor (AhR) E3 ligase. β-Naphthoflavone-CH2-OH can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs (e.g., β-naphthoflavone-JQ1) that recruit the AhR E3 ligase complex by incorporating AhR ligands into chimeric molecules. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-138845A

Pomalidomide-C4-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-130964B

Thalidomide-PEG4-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG4-NH2 hydrochloride is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-132208

Pomalidomide 4'-PEG2-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide 4'-PEG2-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138784

Thalidomide-PEG5-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-130965

Thalidomide-PEG3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138784A

Thalidomide-PEG5-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-131888A

Pomalidomide-C3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-141010B

Thalidomide-O-PEG4-amine TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-PEG4-amine TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-112617B

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride incorporates an E3 ligase ligand and a linker, can be an immunomodulater for the treatment of cancer.

HY-129395

Mezigdomide CC-92480	E1/E2/E3 Enzyme Molecular Glues Apoptosis	Cancer
Mezigdomide (CC-92480), a cereblon E3 ubiquitin ligase modulating agent (CELMoD), acts as a molecular glue. Mezigdomide shows high affinity to cereblon, resulting in potent antimyeloma activity.

HY-133484

Thalidomide-PEG2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138845

Pomalidomide-C4-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-131888

Pomalidomide-C3-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-110287

Apcin	APC	Cancer
Apcin, a ligand of Cdc20, is a potent and competitive anaphase-promoting complex/cyclosome (APC/C(Cdc20)) E3 ligase activity inhibitor. Apcin competitively inhibits APC/C-dependent ubiquitylation by binding to Cdc20 and preventing substrate recognition. Apcin occupes the D-box-binding pocket on the side face of the WD40-domain and can prolong mitosis.

HY-128836

(4R,5S)-Nutlin carboxylic acid MDM2 ligand 2; E3 ligase Ligand 15	Ligands for E3 Ligase	Cancer
(4R,5S)-Nutlin carboxylic acid (MDM2 ligand 2) is the Nutlin 3-based MDM2 ligand. (4R,5S)-Nutlin carboxylic acid can be connected to the ligand for protein by a linker to form PROTACs.

HY-115446A

Lenalidomide-C4-NH2 hydrochloride Cereblon ligand 1 hydrochloride; E3 ligase Ligand-Linker Conjugates 32 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-C4-NH2 hydrochloride is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C4-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC (Compound 24), which has IC₅₀s of 0.98 nM and 13.7 nM in inhibition of RS4;11 and MOLM-13 acute leukemia cell lines growth, respectively.

HY-129776

K-Ras ligand-Linker Conjugate 2	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 2 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 2 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-129775

K-Ras ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 1 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 1 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-138642

Vepdegestrant ARV-471	Estrogen Receptor/ERR PROTACs	Cancer
Vepdegestrant (ARV-471) is an oral estrogen receptor PROTAC protein degrader for breast cancer. Vepdegestrant is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex. Vepdegestrant leads to the ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. Vepdegestrant robustly degrades ER in ER-positive breast cancer cell lines with a half-maximal degradation concentration (DC₅₀) of ~2 nM.

HY-138789

Thalidomide-Piperazine-PEG1-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Piperazine-PEG1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138848

Thalidomide-O-C5-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-10984S2

Pomalidomide-d4 CC-4047-d₄	Molecular Glues Ligands for E3 Ligase Apoptosis	Cancer
Pomalidomide-d₄ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<

HY-133816A

Pomalidomide-amino-PEG5-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amino-PEG5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-136162A

Thalidomide 4'-ether-alkylC2-amine	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide 4'-ether-alkylC2-amine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-133485B

Thalidomide-O-C8-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138847

Thalidomide-O-C3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-133817

Pomalidomide-amino-PEG3-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amino-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-130949

Thalidomide-O-C7-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C7-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138858A

Thalidomide-amido-PEG2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-amido-PEG2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-134986

Thalidomide-NH-C5-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138848A

Thalidomide-O-C5-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-133817A

Pomalidomide-amino-PEG3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amino-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-130948

Thalidomide-O-C4-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138787

Thalidomide-Piperazine-PEG3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Piperazine-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-133816

Pomalidomide-amino-PEG5-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amino-PEG5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138859

Pomalidomide-amino-PEG4-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amino-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-131867

Thalidomide-NH-PEG1-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-PEG1-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138846A

Thalidomide-NH-C8-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138858

Thalidomide-amido-PEG2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-amido-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-136237

Thalidomide-NH-C5-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C5-NH2 hydrochloride is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-130963

Thalidomide-O-C10-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C10-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138847A

Thalidomide-O-C3-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-129704B

Thalidomide-NH-C6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-135250

Thalidomide-O-C6-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138846

Thalidomide-NH-C8-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-133485

Thalidomide-O-C8-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-10984S

Pomalidomide-d5 CC-4047-d₅	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Pomalidomide-d₅ is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

HY-134985

Thalidomide-NH-PEG1-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-PEG1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-129704

Thalidomide-NH-C6-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C6-NH2 is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-136162

Thalidomide 4'-ether-alkylC2-amine hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide 4'-ether-alkylC2-amine hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138788

Thalidomide-Piperazine-PEG2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Piperazine-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138859A

Pomalidomide-amino-PEG4-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amino-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-107444

PROTAC Her3-binding moiety 1
Ligands for Target Protein for PROTAC Cancer

PROTAC HER3-binding moiety 1 (compound 1b) is a Her3 Ligand for PROTAC.

HY-129704A

Thalidomide-NH-C6-NH2 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C6-NH2 TFA is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-134984A

Thalidomide-NH-amido-C4-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-139999A

LCL-PEG3-N3 hydrochloride	Ligands for E3 Ligase	Cancer
LCL-PEG3-N3 (hydrochloride) is a decoy oligonucleotide ligand for E3 ligase which can be used for developing chimeric molecules LCL-ER(dec), degrading the estrogen receptor.

HY-134984

Thalidomide-NH-amido-C4-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138852A

Thalidomide-NH-amido-C6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138788A

Thalidomide-Piperazine-PEG2-NH2 diTFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Piperazine-PEG2-NH2 diTFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-139999

LCL-PEG3-N3	Ligands for E3 Ligase	Cancer
LCL-PEG3-N3 is a decoy oligonucleotide ligand for E3 ligase which can be used for developing chimeric molecules LCL-ER(dec), degrading the estrogen receptor.

HY-123937

THAL-SNS-032	PROTACs CDK	Cancer
THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).

HY-138853

Thalidomide-NH-amido-C8-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-130845

AR antagonist 1	Ligands for E3 Ligase Ligands for Target Protein for PROTAC	Cancer
AR antagonist 1 (compound 29) is a potent androgen receptor (AR) antagonist and binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266 (HY-133020).

HY-137538

Pomalidomide-PEG3-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG3-azide is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-138789A

Thalidomide-Piperazine-PEG1-NH2 diTFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-Piperazine-PEG1-NH2 diTFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138849A

Thalidomide-NH-amido-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138850A

Thalidomide-NH-amido-C3-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138850

Thalidomide-NH-amido-C3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138851

Thalidomide-NH-amido-C5-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-131998

Thalidomide-NH-PEG4-Ms	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-PEG4-Ms is an E3 ligase ligand-linker conjugate that incorporates Thalidomide based cereblon ligand and a linker used for PROTAC BCL-XL degrader XZ739.

HY-138852

Thalidomide-NH-amido-C6-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-136161

Pomalidomide-PEG6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology.

HY-130639

Thalidomide-NH-C4-NH-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C4-NH-Boc (compound 15) is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-137537

Pomalidomide-PEG2-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG2-azide is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-138853A

Thalidomide-NH-amido-C8-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-128767

VH032-PEG3-acetylene	E3 Ligase Ligand-Linker Conjugates	Cancer
VH032-PEG3-acetylene is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.

HY-138851A

Thalidomide-NH-amido-C5-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-141423

Thalidomide-O-amide-C5-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amide-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138849

Thalidomide-NH-amido-C2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-107445

*PROTAC BRD9-binding moiety* 1**	Ligands for Target Protein for PROTAC	Cancer
PROTAC BRD9-binding moiety 1 is a compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.

HY-107445A

*PROTAC BRD9-binding moiety* 1 hydrochloride**	Ligands for Target Protein for PROTAC	Cancer
PROTAC BRD9-binding moiety 1 hydrochloride is a compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.

HY-147373

DA-PROTAC	PROTACs Ligands for E3 Ligase	Cancer
DA-PROTAC is a potent PROTAC degrader of copper ion-transport proteins Atox1 and CCS. DA-PROTAC can bind both Atox1 and CCS proteins, and the complex can be bound to E3 ligase, leading to increased levels of ubiquitination of Atox1 and CCS and degradation of Atox1 and CCS proteins via the proteasome pathway. DA-PROTAC can be used for triple negative breast cancer research.

HY-138786

Thalidomide-5-PEG3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-5-PEG3-NH2 is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-N0170

Indole-3-carbinol I3C; 3-Indolemethanol	NF-κB Aryl Hydrocarbon Receptor E1/E2/E3 Enzyme Endogenous Metabolite	Cancer
Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).

HY-107438A

Thalidomide-O-amido-C4-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-136166

Thalidomide-NH-PEG3-propionic acid	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-PEG3-propionic acid is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-130948B

Thalidomide-O-C4-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide (HY-14658) based cereblon ligand and a linker used in PROTAC technology.

HY-107439A

Thalidomide-O-amido-C8-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-C8-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-112618B

Thalidomide-O-amido-C6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-C6-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-122694

Thalidomide-O-amido-PEG-C2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-PEG-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138786A

Thalidomide-5-PEG3-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-5-PEG3-NH2 is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-141423A

Thalidomide-O-amide-C5-NH2 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amide-C5-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-15694

SMIP004	E1/E2/E3 Enzyme Apoptosis	Cancer
SMIP004 is a SKP2 E3 ligase inhibitor, which downregulates SKP2 and to stabilise p27. SMIP004 is a cancer cell selective apoptosis inducer of human prostate cancer cells.

HY-138785A

Thalidomide-5-PEG4-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-5-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-130845A

AR antagonist 1 hydrochloride	Ligands for E3 Ligase Ligands for Target Protein for PROTAC Androgen Receptor	Cancer
AR antagonist 1 (compound 29) hydrochloride is a potent androgen receptor (AR) antagonist and binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC ARD-266 (HY-133020).

HY-138785

Thalidomide-5-PEG4-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-5-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-44103

Desmethyl-QCA276 PROTAC BRD4-binding Moiety 4	Ligands for Target Protein for PROTAC	Cancer
Desmethyl-QCA276 (PROTAC BRD4-binding moiety 4), the QCA276-based moiety, binds to cereblon ligand via a linker to form PROTAC to degrade BET. QCA276 is a BET inhibitor with an IC₅₀ of 10 nM, and with a K_i of 2.3 nM.

HY-130816

(S,R,S)-AHPC-O-Ph-PEG1-NH2 VH032-O-Ph-PEG1-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-O-Ph-PEG1-NH2 (VH032-O-Ph-PEG1-NH2) is E3 ligase ligand-linker conjugate and incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-O-Ph-PEG1-NH2 is used in PROTAC EED degrader-1 (HY-130614). PROTAC EED degrader-1 is a PROTAC targeting EED with a pK_D of 9.02.

HY-129917

KB02-JQ1	PROTACs Epigenetic Reader Domain	Cancer
KB02-JQ1 is a highly selective and PROTAC-based BRD4 degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes BRD4 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. JQ1 binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-JQ1.

HY-135250B

Thalidomide-O-C6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C6-NH2 hydrochloride is a synthesized *E3 ligase* ligand-linker conjugate** used in the PROTAC dTAG-13, a degrader of FKBP12^F36V and BET.

HY-10984S1

Pomalidomide-d3 CC-4047-d₃	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Pomalidomide-d₃ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors[1][2].

HY-122694A

Thalidomide-O-amido-PEG-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-PEG-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-148130

Rugonersen RG6091; RO7248824	E1/E2/E3 Enzyme	Others
Rugonersen (RG6091; RO7248824) is a locked-nucleic acid (LNA)- modified antisense oligonucleotides (ASOs), and results in reduction of ubiquitin-protein ligase E3A (UBE3A) silencing. Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by the loss of neuronal E3 ligase UBE3A, Rugonersen has been used for AS reasearch.

HY-130716

Thalidomide-NH-C10-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C10-COOH (compound 6b) is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based von Hippel-Lindau (VHL) ligand and a linker used in PROTAC technology.

HY-138862

(S,R,S)-AHPC-C1-Br	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.

HY-141432

Cbl-b-IN-3	E1/E2/E3 Enzyme	Cancer
Cbl-b-IN-3 (Compound 23) is a casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) inhibitor with an IC₅₀ of < 1 nM. Cbl-b is an E3 ubiquitin ligase that negatively regulates T-cell activation.

HY-131232

Desmorpholinyl Navitoclax-NH-Me Desmorpholinyl ABT-263-NH-Me	Bcl-2 Family Ligands for Target Protein for PROTAC	Cancer
Desmorpholinyl Navitoclax-NH-Me is a Bcl-xL inhibitor. Desmorpholinyl Navitoclax-NH-Me and a CRBN ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC BCL-XL degrader XZ739 (HY-133557).

HY-136163A

(S,R,S)-AHPC-C2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.

HY-111760

NRX-252262	Molecular Glues β-catenin	Cancer
NRX-252262 is a potent enhancer of the interaction between β-Catenin, and its cognate E3 ligase, SCF^β-TrCP, induces mutant β-catenin degradation, with an EC₅₀ of 3.8 nM.

HY-153357

NRX-0492	Btk	Cancer
NRX-0492 is an orally active and potent degrader of BTK. NRX-0492 catalyzes ubiquitylation and proteasomal degradation of BTK with DC₅₀≤0.2 nM and DC₉₀≤0.5 nM, respectively. NRX-0492 inhibits B-cell receptor (BCR)-mediated signaling, transcriptional programs, and chemokine secretion. Moreover, NRX-0492 also links a noncovalent BTK-binding domain to Cereblon. Cereblon is an adaptor protein of the E3 ubiquitin ligase complex.

HY-141431

Cbl-b-IN-2	E3 Ligase Ligand-Linker Conjugates	Cancer Inflammation/Immunology
Cbl-b-IN-2 (Example 8) is an orally bioavailable compound, can inhibit the E3 enzyme Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases amenable to immune system modulation. Cbl-b-IN-2 (Example 8) also may be administered to an individual with cancer, either alone or as part of a combination, with one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation agent.

HY-122710

Thalidomide-O-amido-PEG4-C2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-135844

LS-102	E1/E2/E3 Enzyme	Inflammation/Immunology
LS-102 is a selective E3 ubiquitin ligase synoviolin (Syvn1) inhibitor. LS-102 inhibits the autoubiquitination of synoviolin with an IC₅₀ of 35 μM. LS-102 has the potential for rheumatoid arthritis treatment.

HY-131308

Thalidomide-NH-C2-PEG3-OH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C2-PEG3-OH is an E3 ligase ligand-linker conjugate that incorporates Thalidomide based cereblon ligand and a linker used for PROTAC BCL-XL degrader XZ739.

HY-138856A

Thalidomide-NH-amido-PEG3-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-PEG3-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-136163

(S,R,S)-AHPC-C2-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C2-NH2 dihydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-OH can be used in the synthesis of a series of PROTACs.

HY-138856

Thalidomide-NH-amido-PEG3-C2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138854A

Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-112599B

Pomalidomide-PEG4-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in the synthesis of PROTACs..

HY-138855A

Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-136183

(S,R,S)-AHPC-phenol-alkylC6-amine dihydrochloride VH032 phenol-alkylC6-amine dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-phenol-alkylC6-amine dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and an alkyl linker used for PROTAC degrader.

HY-108372

Boc-C5-O-C5-O-C6-Cl PROTAC Linker 2	PROTAC Linkers	Cancer
Boc-C5-O-C5-O-C6-Cl (PROTAC Linker 2) is a PROTAC linker utilized to connect the respective tyrosine kinase inhibitor (TKI) to the E3 recruiting ligand.

HY-137531

Pomalidomide-PEG1-C2-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG1-C2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology.

HY-138854

Thalidomide-NH-amido-PEG1-C2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-PEG1-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138855

Thalidomide-NH-amido-PEG2-C2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-PEG2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138857A

Thalidomide-NH-amido-PEG4-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-138857

Thalidomide-NH-amido-PEG4-C2-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-amido-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

HY-A0003A

Lenalidomide hydrochloride CC-5013 hydrochloride	Ligands for E3 Ligase Molecular Glues	Cancer Inflammation/Immunology
Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator. Lenalidomide hydrochloride (CC-5013 hydrochloride) is a *ligand of ubiquitin E3 ligase* cereblon (CRBN)*, and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase*. Lenalidomide hydrochloride (CC-5013 hydrochloride) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

HY-A0003B

Lenalidomide hemihydrate CC-5013 hemihydrate	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a *ligand of ubiquitin E3 ligase* cereblon (CRBN)*, and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase*. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

HY-46531

Thalidomide-5-NH2-CH2-COOH	Ligands for E3 Ligase	Cancer Inflammation/Immunology
Thalidomide-5-NH2-CH2-COOH (compound 114) is a potent and selective inhibitor of tropomyosin receptor kinase (trk). Thalidomide-5-NH2-CH2-COOH is a ligand of E3 ligase. Thalidomide-5-NH2-CH2-COOH has the potential for researching one or more diseases (extracted from patent WO2021170109A1).

HY-A0003

Lenalidomide CC-5013	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer Inflammation/Immunology
Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a *ligand of ubiquitin E3 ligase* cereblon (CRBN)*, and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase*. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

HY-107452

SLF-amido-C2-COOH PROTAC FKBP12-binding Moiety 1	Ligands for Target Protein for PROTAC FKBP	Cancer
SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) is a synthetic ligand for FKBP (SLF). SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) can be used in the synthesis of PROTACs.

HY-114176B

(S,R,S)-AHPC-C4-NH2 dihydrochloride VH032-C4-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C4-NH2 dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.

HY-133144

Lenalidomide-OH	Ligands for E3 Ligase	Cancer
Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BTK degrader SJF620 (HY-133137).

HY-122710A

Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.

HY-146237

Golcadomide CC-99282	Ligands for E3 Ligase Molecular Glues	Cancer
Golcadomide (CC-99282) is a potent and orally active cereblon (CRBN) E3 ligase modulator (CELMoD). Golcadomide co-opts CRBN to induce potent and targeted degradation of Ikaros and Aiolos. Golcadomide can be used for researching non-Hodgkin lymphomas.

HY-128842

PROTAC MDM2 Degrader-3	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-3 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

HY-128843

PROTAC MDM2 Degrader-4	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-4 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-4 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

HY-128840

PROTAC MDM2 Degrader-1	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-1 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-1 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

HY-128841

PROTAC MDM2 Degrader-2	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-2 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-2 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

HY-138861A

(S,R,S)-AHPC-C1-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C1-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.

HY-148671

(S,R,S)-AHPC-amido-C7-acid	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-amido-C7-acid incorporates a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. (S,R,S)-AHPC-amido-C5-acid can be used to design PROTACs.

HY-114176A

(S,R,S)-AHPC-C4-NH2 VH032-C4-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.

HY-138861

(S,R,S)-AHPC-C1-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.

HY-145818

JPS035	HDAC PROTACs	Cancer
JPS035 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS035 degrades class I histone deacetylase (HDAC). JPS035 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.

HY-145816

JPS016	HDAC PROTACs	Cancer
JPS016 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS016 degrades class I histone deacetylase (HDAC). JPS016 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.

HY-145819

JPS036	HDAC PROTACs	Cancer
JPS036 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS036 degrades class I histone deacetylase (HDAC). JPS036 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.

HY-145815

JPS014	HDAC PROTACs	Cancer
JPS014 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS014 degrades class I histone deacetylase (HDAC). JPS014 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.

HY-44148

FAK ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates	Cancer
FAK ligand-Linker Conjugate 1 incorporates a ligand for FAK, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). FAK ligand-Linker Conjugate 1 can be extensively used for PROTAC-mediated protein degradation.

HY-148406

(S,R,S)-AHPC-C10-NHBoc	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C10-NHBoc is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the (S,R,S)-AHPC (HY-125845) based VHL ligand and a linker used for BET-Targeted PROTAC.

HY-136165

(S,R,S)-AHPC-PEG3-propionic acid	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG3-propionic acid is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.

HY-135250A

Thalidomide-O-C6-NH2 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-C6-NH2 TFA is a synthesized *E3 ligase* ligand-linker conjugate** used in the PROTAC dTAG-13 (HY-114421), a degrader of FKBP12^F36V and BET.

HY-129523

PROTAC K-Ras Degrader-1	PROTACs Ras	Cancer
PROTAC K-Ras Degrader-1 (Compound 518) is a PROTAC. PROTAC K-Ras Degrader-1 can effectively degrades K-Ras based on Cereblon E3 ligand, exhibits ≥70% degradation efficacy in SW1573 cells.

HY-130988A

Ipatasertib-NH2 dihydrochloride GDC-0068-NH2 dihydrochloride; RG7440-NH2 dihydrochloride	Ligands for Target Protein for PROTAC	Cancer
Ipatasertib-NH2 dihydrochloride is a ligand for target protein AKT for PROTAC (INY-03-041). INY-03-041 is composed of Ipatasertib-NH2, a ten-hydrocarbon linker, and a CRBN ligand Lenalidomide for E3 ubiquitin ligase.

HY-111852

GNF5-amido-Me PROTAC ABL binding Moiety 2	Ligands for Target Protein for PROTAC	Cancer
GNF5-amido-Me, the GNF5 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.

HY-130800

Eragidomide CC-90009	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer Inflammation/Immunology
Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4^CRBN to selectively target GSPT1 for ubiquitination and proteasomal degradation.

HY-131959

(S,R,S)-AHPC-PEG5-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG5-Boc is a E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for Cdc20 degrader CP5V.

HY-131872

Pomalidomide-PEG2-COOH Pomalidomide 4'-PEG2-acid	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG2-COOH (Pomalidomide 4'-PEG2-acid) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

HY-131912

Thalidomide-NH-PEG8-Ts	E3 Ligase Ligand-Linker Conjugates	Inflammation/Immunology
Thalidomide-NH-PEG8-Ts is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and 8-unit PEG linker used in PROTAC technology, such as IDO1 PROTAC degrader (HY-131911).

HY-136160

Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride can be used to design the PROTACs.

HY-144841

Cemsidomide CFT7455	Ligands for E3 Ligase	Cancer
Cemsidomide (CFT7455) is an orally active zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3) degrader. Cemsidomide is an anti-cancer agent that binds with high affinity to the cereblon E3 ligase (K_d of 0.9 nM) (WO2022032132A1; Compound 1).

HY-131318

Lenalidomide-I	Ligands for E3 Ligase	Cancer
Lenalidomide-I (Compound 72), an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, is used in the recruitment of CRBN protein. Lenalidomide-I can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BET degrader QCA570 (HY-112609).

HY-136688

MI-389	PROTACs	Cancer
MI-389 is a PROTAC translation termination factor GSPT1 degrader. MI-389 disrupts a target that is a shared dependency in different AML and ALL cell lines, and that MI-389 action is dependent on the CRL4^CRBN E3 ligase.

HY-111857

Dasatinib carbaldehyde BMS-354825 carbaldehyde; PROTAC ABL binding Moiety 4	Ligands for Target Protein for PROTAC	Cancer
Dasatinib carbaldehyde (BMS-354825 carbaldehyde), the Dasatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .

HY-130648

Thalidomide-NH-PEG7	Drug-Linker Conjugates for ADC E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate for ADC. Thalidomide-NH-PEG7 can be connected to the ligand for protein by a linker to form PROTAC iRucaparib-AP6, a highly specific PARP1 degrader.

HY-107440A

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-130835

FKBP12 PROTAC RC32 RC32	PROTACs FKBP	Cancer
FKBP12 PROTAC RC32 (RC32) is a potent FKBP12 degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an Cereblon E3 ubiquitin ligase (Pomalidomide; HY-10984).

HY-130297

PROTAC BCR-ABL1 ligand 1	Bcr-Abl	Cancer
PROTAC BCR-ABL1 ligand 1, compound GMB-475, is the ligand of PROTAC that allosterically targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel-Lindau, resulting in ubiquitination and subsequent degradation of BCR-ABL1.

HY-134591

Thalidomide-NH-PEG4-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate which can be used for synthesizing dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP.

HY-122702

PEG6-(CH2CO2H)2	PROTAC Linkers	Others
PEG6-(CH2CO2H)2 is a symmetric PEG PROTAC linker, for the synthesis of Homo-PROTACs which is bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.

HY-131190

N-Boc-SBP-0636457-O-C3-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
N-Boc-SBP-0636457-OH is a synthesized E3 ligase ligand-linker conjugate that incorporates IAP ligand and a linker. N-Boc-SBP-0636457-OH can be used to design a PROTAC Bcl-xL degrader-1 (HY-131188).

HY-132992

EN219-O-C4-NH2 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
EN219-O-C4-NH2 TFA incorporates an E3 ubiquitin ligase ligand, and a PROTAC linker. EN219-O-C4-NH2 TFA can be used to design PROTACs.

HY-130737

Pomalidomide 4'-alkylC5-acid	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide 4'-alkylC5-acid (Example 3) is an E3 ligase ligand-linker conjugate containing a Pomalidomide (HY-10984) based cereblon (CRBN) ligand and a linker. Pomalidomide 4'-alkylC5-acid can be used in the synthesis of PROTAC.

HY-131646

Thalidomide-O-amido-C3-PEG3-C1-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

HY-130638

(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc VH032-O-Ph-PEG1-NH-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc (VH032-O-Ph-PEG1-NH-Boc) is a synthesized *E3 ligase* ligand-linker conjugate** which is used for the EED-targeted PROTAC.

HY-111855

HG-7-85-01-Decyclopropane PROTAC ABL binding Moiety 3	Ligands for Target Protein for PROTAC	Cancer
HG-7-85-01-Decyclopropane, the HG-7-85-01 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .

HY-131647

Pomalidomide 4'-PEG5-acid Pomalidomide-PEG5-CO2H	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide 4'-PEG5-acid (Pomalidomide-PEG5-CO2H) is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Pomalidomide based cereblon ligand and 5-unit PEG linker used in PROTAC technology.

HY-14658

Thalidomide	Ligands for E3 Ligase Molecular Glues Autophagy Apoptosis Bacterial	Cancer Inflammation/Immunology
Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a K_d of ∼250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties. Thalidomide can work as molecular glue to potentiate substrate.

HY-69220

7-Octynoic acid	PROTAC Linkers	Cancer
7-Octynoic acid (compound 42) is a PROTAC linker and can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-110204

Heclin	E1/E2/E3 Enzyme	Others
Heclin is a HECT E3 ubiquitin ligases inhibitor. Heclin inhibits several HECT ligases in tissue culture cells (IC₅₀s=6.8, 6.3, and 6.9 μM for Smurf2, Nedd4, and WWP1 HECT ligase domains, respectively).

HY-130849

(S,R,S)-AHPC-Me-C5-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-C5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C5-COOH can be used in PROTAC DT2216 (HY-130604).

HY-131186

Pomalidomide-amido-C3-piperazine-N-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amido-C3-piperazine-N-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183).

HY-114324

PROTAC PARP1 degrader	PROTACs PARP	Cancer
PROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC₅₀ of 6.12 μM.

HY-114420

AP1867-2-(carboxymethoxy) PROTAC FKBP12-binding Moiety 2	FKBP Ligands for Target Protein for PROTAC	Cancer
AP1867-2-(carboxymethoxy), the AP1867 (a synthetic FKBP12^F36V-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules.

HY-136008

(S,R,S)-AHPC-PEG1-NH2 VH032-PEG1-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG1-NH2 (VH032-PEG1-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.

HY-136006B

(S,R,S)-AHPC-C6-NH2 VH032-C6-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C6-NH2 (VH032-C6-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.

HY-136186

(S,R,S)-AHPC-C7-amine VH032-C7-amine	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C7-amine (VH032-C7-amine) is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for estrogen-related receptor α (ERRα) PROTAC degrader.

HY-123844

dBET57	PROTACs Epigenetic Reader Domain	Cancer
dBET57 is a potent and selective degrader of BRD4_BD1 based on the PROTAC technology. dBET57 mediates recruitment to the CRL4^Cereblon E3 ubiquitin ligase, with a DC_50/5h of 500 nM for BRD4_BD1, and is inactive on BRD4_BD2.

HY-112811

PROTAC CDK9 degrader-2	PROTACs CDK	Cancer
PROTAC CDK9 degrader-2 (compounds 11c) is a potent and selective CDK9 degrader based on PROTAC, with an IC₅₀ of 17 μM in MCF-7 cell lines. Natural product Wogonin (CDK ligand) binds ubiquitin E3 ligase Cereblon (CRBN) via a linker to form PROTAC.

HY-14658S

Thalidomide D4	Ligands for E3 Ligase Molecular Glues Autophagy Apoptosis	Cancer Inflammation/Immunology
Thalidomide-d₄ is a deuterium labeled Thalidomide. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ~250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties[1][2].

HY-130711B

(S,R,S)-AHPC-C3-NH2 hydrochloride VH032-C3-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.

HY-133487A

(S,R,S)-AHPC-C8-NH2 hydrochloride VH032-C8-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.

HY-145615

Pomalidomide-C12-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-C12-NH2 hydrochloride is the *E3 ligase* ligand-linker conjugate of PROTAC KRAS G12C degrader-1 (HY-139186). PROTAC KRAS G12C degrader-1 is a Cereblon**-based KRAS^G12C degrader.

HY-133139

Lenalidomide-PEG1-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Lenalidomide-PEG1-azide incorporates the Lenalidomide based cereblon ligand and a linker. Lenalidomide-PEG1-azide can be used to design a PROTAC BRD4 Degrader-2 (HY-133136).

HY-111849

Imatinib carbaldehyde CGP-57148B carbaldehyde; STI571 carbaldehyde; PROTAC ABL binding Moiety 1	Ligands for Target Protein for PROTAC	Cancer
Imatinib carbaldehyde (CGP-57148B carbaldehyde), the Imatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.

HY-129941

(S,R,S)-AHPC-C10-NH2 VH032-C10-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C10-NH2 (VH032-C10-NH2) is a synthesized *E3 ligase* ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL** ligand and a linker used for BET-Targeted PROTAC.

HY-129941A

(S,R,S)-AHPC-C10-NH2 dihydrochloride VH032-C10-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C10-NH2 dihydrochloride (VH032-C10-NH2 dihydrochloride) is a synthesized *E3 ligase* ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL** ligand and a linker used for BET-Targeted PROTAC.

HY-133020

ARD-266	PROTACs Androgen Receptor	Cancer
ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM.

HY-108705

BI-3802	Molecular Glues Bcl-2 Family	Cancer
BI-3802 is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC₅₀ of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity.

HY-130713

Thalidomide-C2-amido-C2-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-C2-amido-C2-COOH incorporates a CRBN ligand for the E3 ubiquitin ligase, and a linker. Thalidomide-C2-amido-C2-COOH can be used to design PROTAC CDK2/9 Degrader-1 (HY-130709).

HY-133138

Pomalidomide-PEG1-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-PEG1-azide can be used to design a PROTAC BRD4 Degrader-1 (HY-133131).

HY-112098

PROTAC ERα Degrader-1	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an estrogen receptor-alpha (ERα) degrader.

HY-130847

(S,R,S)-AHPC-Me-C10-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-C10-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C10-NH2 can be used in PROTAC MS432 (HY-130602).

HY-P1348

*GLP-1 moiety* from Dulaglutide**	GCGR	Metabolic Disease
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.

HY-131187

BMS-1166-N-piperidine-COOH	Ligands for Target Protein for PROTAC	Cancer
BMS-1166-N-piperidine-COOH, the BMS-1166-based moiety, binds to E3 ligase ligand via a linker to form PROTAC PD-1/PD-L1 degrader-1 (HY-131183) to degrade PD-1/PD-L1. BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.

HY-103608

(S,R,S)-AHPC-(C3-PEG)2-C6-Cl VHL Ligand-Linker Conjugates 11; E3 ligase Ligand-Linker Conjugates 11	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-(C3-PEG)2-C6-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3-PEG)2-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

HY-136184

(S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride VH032-phenol-C4-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-phenol-C4-NH2 (VH032-phenol-C4-NH2) dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.

HY-141486

(Rac)-PROTAC PARP/EGFR ligand 1	Target Protein Ligand-Linker Conjugates	Cancer
(Rac)-PROTAC PARP/EGFR ligand 1 incorporates a ligand for PARP and EGFR , and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). (Rac)-PROTAC PARP/EGFR ligand 1 can be used in the synthesis of DP-C-4, which is CRBN-based dual PROTAC for simultaneous degradation of EGFR and PARP.

HY-125834

GMB-475	PROTACs Bcr-Abl Apoptosis	Cancer
GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent agent resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.

HY-129652

Halo PROTAC 1	AUTACs	Cancer
Halo PROTAC 1 is a conjugate of ligands for E3 and 22-atom-length linker. The connector of linker is Halogen group. Halo PROTAC 1 is a ligand having activity to bind to an intracellular proteins fused with HaloTag and a structure having activity to induce autophagy of an intracellular molecule are linked via a PEG linker. Halo PROTAC 1 can be uesd for the synthesis of AUTAC.

HY-136187

(S,R,S)-AHPC-C5-NH2 VH032-C5-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C5-NH2 (VH032-C5-NH2) is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for estrogen-related receptor α (ERRα) PROTAC degrader.

HY-108374

4-Azidobutylamine	PROTAC Linkers	Cancer
4-Azidobutylamine is a PROTAC linker, which refers to the alkyl chain composition. 4-Azidobutylamine can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-131385

KB02-COOH	Ligands for E3 Ligase	Cancer
KB02-COOH is a fragment of synthesis of ubiquitin E3 ligase ligand KB02. KB02 can be used in the synthesis of PROTAC, such as KB02-JQ1 (HY-129917) and KB02-SLF (HY-129610).

HY-103603B

(S,R,S)-AHPC-PEG2-NH2 dihydrochloride VH032-PEG2-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG2-NH2 dihydrochloride (VH032-PEG2-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.

HY-107453

SirReal1-O-propargyl PROTAC Sirt2-binding Moiety 1	Ligands for Target Protein for PROTAC	Cancer
SirReal1-O-propargyl is a selective and highly potent Sirtuin 2 (Sirt2) inhibitor, with an IC₅₀ of 2.4 μM. SirReal1-O-propargyl, the SirReal1-based moiety, binds to the cereblon ligand via a linker to form PROTAC to degrade Sirt2.

HY-132296

GSK215	FAK PROTACs	Cancer
GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC₅₀ of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect.

HY-130853

Thalidomide-NH-PEG2-C2-NH-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a PEG linker used for dBRD9 (compound 6) synthesis. dBRD9 is a selective BRD9 probe PROTAC degrader for the study of BAF complex biology.

HY-130988

Ipatasertib-NH2 GDC-0068-NH2; RG7440-NH2	Ligands for Target Protein for PROTAC	Cancer
Ipatasertib-NH2 (GDC-0068-NH2;RG7440-NH2) is a ligand for target protein AKT for PROTAC (INY-03-041). INY-03-041 is composed of Ipatasertib-NH2, a ten-hydrocarbon linker, and a CRBN ligand Lenalidomide for E3 ubiquitin ligase.

HY-136008A

(S,R,S)-AHPC-PEG1-NH2 dihydrochloride VH032-PEG1-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-PEG1-NH2 (VH032-PEG1-NH2) dihydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. (S,R,S)-AHPC-PEG1-NH2 dihydrochloride can be used to design PROTACs.

HY-130854

Thalidomide-NH-C6-NH-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C6-NH-Boc is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and a linker used for MI-389 (compound 22) synthesis. MI-389 is a potent phthalimide PROTAC degrader based on the multi-targeted receptor tyrosine kinase inhibitor sunitinib (HY-10255A).

HY-130256

β-NF-JQ1	PROTACs Epigenetic Reader Domain	Cancer
β-NF-JQ1 is a PROTAC that recruits Aryl Hydrocarbon Receptor E3 ligase to target proteins. β-NF-JQ1 is directed against bromodomain-containing (BRD) proteins using β-NF as an AhR ligand, induces the interaction of AhR and BRD proteins, and displays effective anticancer activity that correlated with protein knockdown activity.

HY-131188

PROTAC Bcl-xL degrader-1	PROTACs Bcl-2 Family	Cancer
PROTAC Bcl-xL degrader-1 is a PROTAC that comprises a Bcl-xL (Bcl-2 family member) ligand binding group, a linker and an IAP E3 ligases binding group. PROTAC Bcl-xL degrader-1 is a potent Bcl-xL degrader, and shows toxicity for human platelets and MyLa 1929 cells with IC₅₀ values of 62 nM and 8.5 μM, respectively.

HY-145479

PROTAC AR-V7 degrader-1	PROTACs Androgen Receptor	Cancer
PROTAC AR-V7 degrader-1 (Compound 6) is a potent, orally bioavailable and selective AR-V7 degrader with the DC₅₀ of 0.32 µM by recruiting VHL E3 ligase to Androgen receptor (AR) DNA binding domain (DBD) binder. PROTAC AR-V7 degrader-1 exhibits activity against 22Rv1 cell-line expressing AR-V7 with the EC₅₀ of 0.88 µM.

HY-129774

Phthalimide-PEG4-MPDM-OH	PROTAC Linkers	Cancer
Phthalimide-PEG4-MPDM-OH is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG4-MPDM-OH can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-130617

Pomalidomide-amido-C1-Br	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-amido-C1-Br is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1 (HY-111758). PROTAC B-Raf degrader 1 has anti-cancer activity.

HY-130982

Lenalidomide-PEG3-iodine	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-PEG3-iodine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based cereblon ligand and a 3-unit PEG linker. Lenalidomide-PEG3-iodine can be used in the synthesis of a series of PROTACs, such as SJF620 (HY-133137). SJF620 is a potent PROTAC BTK degrader with a DC₅₀ of 7.9 nM.

HY-100972

ARV-771	PROTACs Epigenetic Reader Domain	Cancer
ARV-771 is a potent BET PROTAC based on E3 ligase von Hippel-Lindau with K_ds of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), *BRD3(1), BRD3(2), BRD4(1), and BRD4(2)*, respectively.

HY-130715

tert-Butyl 11-aminoundecanoate	PROTAC Linkers	Cancer
tert-Butyl 11-aminoundecanoate (compound 6b) is a PROTAC linker, which refers to the PEG composition. tert-Butyl 11-aminoundecanoate can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-129773

Phthalimide-PEG4-PDM-OTBS	PROTAC Linkers	Cancer
Phthalimide-PEG4-PDM-OTBS is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG4-PDM-OTBS can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-148362

Pomalidomide-C6-O-C5-O-C4-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-C6-O-C5-O-C4-COOH is a E3 ligase ligand-linker conjugate comprising a Pomalidomide (HY-10984)-based cereblon ligand and linker. Pomalidomide-C6-O-C5-O-C4-COOH can be used for the synthesis of PROTACs.

HY-133045

VHL Ligand 8	Ligands for E3 Ligase	Cancer
VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM.

HY-125876

PROTAC Bcl2 degrader-1	PROTACs Bcl-2 Family	Cancer
PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC based on Cereblon ligand, which potently and selectively induces the degradation of Bcl-2 (IC₅₀, 4.94 μM; DC₅₀, 3.0 μM) and Mcl-1 (IC₅₀, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1.

HY-111546

BI-3663	PROTACs FAK	Cancer
BI-3663 is a highly selective PTK2/FAK PROTAC (DC₅₀=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC₅₀ of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker. Anti-cancer activity.

HY-144323

YF135	PROTACs PERK	Cancer
YF135 is an efficient and reversible-covalent KRAS^G12C PROTAC. YF135 is designed and synthesized by tethering KRAS G12C inhibitor 48 (compound 6d) as the ligand, and basing on the scaffold of MRTX849 linkage VHL ligand. YF135 significantly induces the degradation of KRAS^G12C in a reversible manner and decreases phospho-ERK level through the E3 ligase VHL mediated proteasome pathway.

HY-136055

(S,R,S)-AHPC-C5-COOH VH032-C5-COOH	E3 Ligase Ligand-Linker Conjugates HIF/HIF Prolyl-Hydroxylase	Cancer
(S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized E3 ligase ligand-linker conjugate, contains the VH032 VHL-based ligand and a linker to form PROTACs. VH-032 is a selective and potent inhibitor of VHL/HIF-1α interaction with a K_d of 185 nM, has the potential for the study of anemia and ischemic diseases.

HY-131911

PROTAC IDO1 Degrader-1	PROTACs Indoleamine 2,3-Dioxygenase (IDO)	Inflammation/Immunology
PROTAC IDO1 Degrader-1 is the first potent IDO1 (indoleamine 2,3-dioxygenase 1) degrader that hijacks IDO1 to Cereblon E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC₅₀=2.84 μM). PROTAC IDO1 Degrader-1 moderately improves the tumor-killing activity of H ER2 CAR-T cells.

HY-145071

PROTAC ERα Y537S degrader-1	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Y537S degrader-1 comprises a ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Y537S degrader-1 extracts from patent WO2021143822, example 12. PROTAC ERα Y537S degrader-1 is an estrogen receptor-alpha (ERα) Y537S degrader.

HY-130652

Pomalidomide 4'-PEG3-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide 4'-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide-based cereblon ligand and a linker. Pomalidomide 4'-PEG3-azide can be used for the synthesis of iRucaparib-TP3 (Compound 3). iRucaparib-TP3 is a highly efficient PARP1 degrader based on Rucaparib by using the PROTAC approach.

HY-103636

PROTAC Sirt2 Degrader-1	Sirtuin PROTACs	Cancer
PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide Cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC₅₀ of 0.25 μM for Sirt2, with no effect on Sirt1/Sirt3 (IC₅₀s>100 μM).

HY-129772

Phthalimide-PEG3-C2-OTs	PROTAC Linkers	Cancer
Phthalimide-PEG3-C2-OTs (Compound 5) is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG3-C2-OTs can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-40178

NH2-C4-NH-Boc	PROTAC Linkers	Cancer
NH2-C4-NH-Boc (compound 15) is a PROTAC linker, which refers to the Alkyl/ether composition. NH2-C4-NH-Boc can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-110174

NAB2	Others	Neurological Disease
NAB2 is a neuron-protective agent. NAB2 strongly and selectively protects diverse cell types from α-syn toxicity. NAB2 promots endosomal transport events dependent on the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 identifies a agentgable node in the biology of α-syn that can correct multiple aspects of its underlying pathology, including dysfunctional endosomal and endoplasmic reticulum-to-Golgi vesicle trafficking.

HY-130122

MG-277	Molecular Glues PROTACs Apoptosis	Cancer
MG-277, a molecular glue degrader, effectively induces degradation of a translation termination factor based on Cereblon E3 ligand, GSPT1, with a DC₅₀ of 1.3 nM. MG-277 potently inhibits tumor cell growth in a p53-independent manner, with IC₅₀s of 3.5 nM for RS4;11 cells and 3.4 nM for p53 mutant RS4;11/IRMI-2 cells, respectively. Anticancer activity.

HY-151791

(S,R,S)-AHPC-C6-PEG3-butyl-N3	ADC Linker	Others
(S,R,S)-AHPC-C6-PEG3-butyl-N3 is a click chemistry reagent containing an azide group. (S,R,S)-AHPC-C6-PEG3-butyl-N3 serves as crosslinker-E3 ligase ligand conjugate, Click reactive protein degrader building block for PROTAC research, Template for synthesis of targeted protein degrader, VH032 conjugate.

HY-131168

(S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH VH032-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH (VH032-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH) is a E3 ligase ligand-linker conjugate that contains on one end a VHL ligand. (S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH is used in PROTAC technology.

HY-129619

SNIPER(ER)-87	SNIPERs Estrogen Receptor/ERR	Cancer
SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor α (ERα) ligand 4-hydroxytamoxifen by a PEG linker, and efficiently degrades the ERα protein (IC₅₀=0.097 μM). SNIPER(ER)-87 preferentially recruits XIAP to ERα in the cells, and XIAP is the primary E3 ubiquitin ligase responsible for the SNIPER(ER)-87-induced ERα degradation.

HY-123941

FKBP12 PROTAC dTAG-7 dTAG-7	PROTACs FKBP Epigenetic Reader Domain	Cancer
FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional degrader. FKBP12 PROTAC dTAG-7 (dTAG-7) is a degrader of FKBP12^F36V with expression of FKBP12^F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-7 (dTAG-7) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin ligase CRBN.

HY-W050162

*(E)-3,4,5-Trimethoxycinnamic acid* TMCA	GABA Receptor 5-HT Receptor	Neurological Disease
(E)-3,4,5-Trimethoxycinnamic acid (TMCA) is a cinnamic acid substituted by multi-methoxy groups. (E)-3,4,5-Trimethoxycinnamic acid is an orally active and potent GABA_A/BZ receptor agonist. (E)-3,4,5-Trimethoxycinnamic exhibits favourable binding affinity to 5-HT_2C and 5-HT_1A receptor, with IC₅₀ values of 2.5 and 7.6 μM, respectively. (E)-3,4,5-Trimethoxycinnamic acid shows anticonvulsant and sedative activity. (E)-3,4,5-Trimethoxycinnamic acid can be used for the research of insomnia, headache and epilepsy.

HY-130618

Boc-C1-PEG3-C4-OH	PROTAC Linkers	Cancer
Boc-C1-PEG3-C4-OH is a PROTAC linker, which refers to the Alkyl/ether composition. Boc-C1-PEG3-C4-OH can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-133487

(S,R,S)-AHPC-C8-NH2 dihydrochloride VH032-C8-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer Inflammation/Immunology
(S,R,S)-AHPC-C8-NH2 dihydrochloride (VH032-C8-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1.

HY-136006

(S,R,S)-AHPC-C6-NH2 dihydrochloride VH032-C6-NH2 dihydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer Inflammation/Immunology
(S,R,S)-AHPC-C6-NH2 dihydrochloride (VH032-C6-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 dihydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1.

HY-133487B

(S,R,S)-AHPC-C8-NH2 VH032-C8-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer Inflammation/Immunology
(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1.

HY-137516

LC-2	PROTACs Ras	Cancer
LC-2 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC₅₀s between 0.25 and 0.76 μM. LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines.

HY-136006A

(S,R,S)-AHPC-C6-NH2 hydrochloride VH032-C6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer Inflammation/Immunology
(S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 hydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1.

HY-130422

Tos-PEG4-t-butyl ester Tos-PEG4-Boc	PROTAC Linkers	Cancer
Tos-PEG4-t-butyl ester (Tos-PEG4-Boc) is a PROTAC linker, which refers to the PEG composition. Tos-PEG4-t-butyl ester (Tos-PEG4-Boc) can be used in the synthesis of a series of PROTACs, such as BI-3663 (HY-111546). BI-3663 is a highly selective PTK2/FAK PROTAC, with cereblon ligands to hijack E3 ligases for PTK2 degradation, and inhibits PTK2 with an IC₅₀ of 18 nM.

HY-130711A

(S,R,S)-AHPC-C3-NH2 TFA VH032-C3-NH2 TFA	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C3-NH2 TFA (VH032-C3-NH2 TFA) is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader.

HY-130711

(S,R,S)-AHPC-C3-NH2 VH032-C3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader.

HY-R01681

hsa-miR-548e-3p mimic	MicroRNA	Cancer
hsa-miR-548e-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-R01601

hsa-miR-520e-3p mimic	MicroRNA	Cancer
hsa-miR-520e-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-R03202

mmu-miR-467e-3p mimic	MicroRNA	Cancer
mmu-miR-467e-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-R00543

hsa-miR-30e-3p mimic	MicroRNA	Cancer
hsa-miR-30e-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-R03049

mmu-miR-344e-3p mimic	MicroRNA	Cancer
mmu-miR-344e-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-R01572

hsa-miR-518e-3p mimic	MicroRNA	Cancer
hsa-miR-518e-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-R03465

mmu-miR-669e-3p mimic	MicroRNA	Cancer
mmu-miR-669e-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-R00009

hsa-let-7e-3p mimic	MicroRNA	Cancer
hsa-let-7e-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-R01593

hsa-miR-519e-3p mimic	MicroRNA	Cancer
hsa-miR-519e-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-W068771

*(E)-3-(4-Methoxyphenyl)acrylic acid*	Endogenous Metabolite	Metabolic Disease Neurological Disease
(E)-3-(4-Methoxyphenyl)acrylic acid (compound 3) is isolated from Arachis hypogaea, Scrophularia buergeriana Miquel, Aquilegia vulgaris, Anigozanthos preissii and so on. (E)-3-(4-Methoxyphenyl)acrylic acid shows significant hepatoprotective activity, anti-amnesic, cognition-enhancing activity, antihyperglycemic, and neuroprotective activities.

HY-A0003S

Lenalidomide-d5 CC-5013-d₅	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer Inflammation/Immunology
Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

HY-151792

Pomalidomid-C6-PEG3-butyl-N3	PROTACs	Cancer Metabolic Disease Inflammation/Immunology
Pomalidomid-C6-PEG3-butyl-N3 is a click chemistry reagent containing an azide group. Pomalidomid-C6-PEG3-butyl-N3 also is a crosslinker-E3 ligase ligand conjugate, which be used in click reactive protein degrader building block for PROTAC research. Pomalidomid-C6-PEG3-butyl-N3 also can be used in the template for synthesis of targeted protein degrader.

HY-131387

(S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 can be used in PROTAC BRD4 Degrader-5 (HY-133737) and PROTAC BRD4 Degrader-5-CO-PEG3-N3 (HY-133736).

HY-N1414

*(E)-3',6-Disinapoylsucrose*	Others	Neurological Disease
(E)-3',6-Disinapoylsucrose, the index component of Yuanzhi (Polygala tenuifolia Willd), possesses potent antioxidant activity and antidepressant effect.

HY-130619

Boc-C1-PEG3-C4-OBn	PROTAC Linkers	Cancer
Boc-C1-PEG3-C4-OBn (PROTAC Linker 15) is a PROTAC linker, which refers to the PEG composition. Boc-C1-PEG3-C4-OBn can be used in the synthesis of a series of PROTACs, such as PROTAC SGK3 degrader-1 (HY-125878). PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

HY-129602

SD-36	PROTACs STAT Apoptosis	Cancer
SD-36 is a potent and efficacious *STAT3* PROTAC degrader (K_d=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC₅₀=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase.

HY-142444

SSAO/VAP-1 inhibitor 1	AP-1	Metabolic Disease
SSAO/VAP-1 inhibitor 1 is a potent inhibitor of SSAO/VAP-1. SSAO/VAP-1 promotes the transfer of Glucose transport 4 (GLUT 4) from adipocytes to the cell membrane, thereby regulating glucose transport. In endothelial cells, SSAO/VAP-1 can mediate the adhesion and exudation of leukocytes and endothelial cells, and participate in inflammatory responses. SSAO/VAP-1 inhibitor 1 has the potential for the research of inflammation and/or inflammation-related disease or diabetes and/or diabetes-related disease (extracted from patent WO2021102774A1, compound E3).

HY-112495

VH032-PEG5-C6-Cl HaloPROTAC 2	E3 Ligase Ligand-Linker Conjugates	Cancer
VH032-PEG5-C6-Cl (HaloPROTAC 2) is a conjugate of ligands for E3 and 21-atom-length linker. The connector of linker is Halogen group. VH032-PEG5-C6-Cl incorporates the VH032 based VHL ligand and 5-unit PEG linker. VH032-PEG5-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

HY-W012845A

*(E)-3-(2-Furyl)acrolein*	Biochemical Assay Reagents	Others
(E)-3-(2-Furyl)acrolein is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-148204

Gallichrome	Bacterial	Infection
Gallichrome is an active peptide. Gallichrome can interact directly with the hydroxamate moieties of the siderophore. Gallichrome can be used for the research of the uptake of iron in many gram-positive and gramnegative bacteria.

HY-145177

Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate. Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc can be used for the synthesis of PROTAC BET degrader. (From patent WO2017180417A1 compound s7).

HY-138102

SSAA09E3	SARS-CoV	Infection
SSAA09E3 is a SARS-CoV entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC₅₀ of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC₅₀ of 0.15 μM.

HY-P9934

Abciximab C7E3	Integrin	Cardiovascular Disease
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.

HY-W068783

*(E)-3,4-(Methylenedioxy)cinnamic acid* (E)-Piperonylprop-2-enoic acid	Endogenous Metabolite	Others
(E)-3,4-(Methylenedioxy)cinnamic acid is a cinnamic acid derivative obtained from the stem bark of Brombya platynema.

HY-N11650

(22S,24E)-3β,22-Diacetoxylanosta-7,9(11),24-trien-26-oic acid	Bacterial	Infection
(22S,24E)-3β,22-Diacetoxylanosta-7,9(11),24-trien-26-oic acid (compound 15) is an antitubercular agent with MIC value of 12.5 μg/mL for Mycobacterium tuberculosis H37Ra. (22S,24E)-3β,22-Diacetoxylanosta-7,9(11),24-trien-26-oic acid shows cytotoxicity with IC₅₀ value of 32 μM for Vero cells.

HY-131183

PROTAC PD-1/PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner.

HY-130654

(S,R,S)-AHPC-C2-PEG4-N3 VH032-C2-PEG4-N3	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized *E3 ligase* ligand-linker conjugate** that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. (S,R,S)-AHPC-C2-PEG4-N3 can be used in the synthesis of vRucaparib-TP4 (HY-130647). vRucaparib-TP4 a highly potent PARP1 degrader with a half-maximal degrading concentration (DC₅₀) of 82 nM.

HY-148154

Poly(oxy-1,2-ethanediyl)-propoxy-amide-C6	Others	Others
Poly(oxy-1,2-ethanediyl)-propoxy-amide-C6 (n=450) is an active compound. Poly(oxy-1,2-ethanediyl)-propoxy-amide-C6 is a small molecule moiety for pegylation modification in Avacincaptad pegol (HY-147080).

HY-N10383

(1E)-3-Methoxy-8,12-epoxygermacra-1,7,10,11-tetraen-6-one	Others	Others
(1E)-3-Methoxy-8,12-epoxygermacra-1,7,10,11-tetraen-6-one (Compound 4) is a natural compound which can be derived from resins obtained from Commiphora sphaerocarpa.

HY-N1778A

*(E)-3,4-Dimethoxycinnamic acid* (E)-O-Methylferulic acid	Reactive Oxygen Species Virus Protease	Cancer Infection
(E)-3,4-Dimethoxycinnamic acid is the less active isomer of 3,4-Dimethoxycinnamic acid. 3,4-Dimethoxycinnamic acid exerts anti-apoptotic effects on L-02 cells via the ROS-mediated signaling pathway. Anti-apoptotic effects.

HY-N3796

Echinulin Echinuline	NF-κB	Inflammation/Immunology
Echinulin (Echinuline) is a cyclic dipeptide carrying a triprenylated indole moiety. Echinulin contributes to the activation of T cell subsets, which leads to NF-κB activation.Echinulin exerts its immune roles by the NF-κB pathway.Echinulin has the potential to serve as a immunotherapeutic agent.

HY-10082A

*(E)-3-AP* (E)-PAN-811; (E)-NSC# 663249; (E)-OCX191	DNA/RNA Synthesis	Cancer
(E)-3-AP is the E configuration of 3-AP. 3-AP is a potent ribonucleotide reductase inhibitor. 3-AP shows anti-proliferative activity. 3-AP shows anticancer activity in L1210 leukemia model. 3-AP inhibits RR activity and DNA synthesis.

HY-111850

Bestatin-amido-Me
PROTAC IAP binding Moiety 1
Ligands for E3 Ligase Cancer

Bestatin-amido-Me, the Bestatin-based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER.

HY-148153

C6-Amide-(PEG)n-CH3	Others	Inflammation/Immunology
C6-Amide-(PEG)n-CH3 (n=310) is an active compound. C6-Amide-(PEG)n-CH3 is a small molecule moiety for PEGylation in Egaptivon pegol (HY-147079) that can be used for the research of platelet dysfunction disorders.

HY-111853

MV-1-NH-Me
PROTAC IAP binding Moiety 2
Ligands for E3 Ligase Cancer

MV-1-NH-Me, the MV-1 based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER.

HY-125908

A-1210477-piperazinyl PROTAC Mcl1-binding Moiety 1	Ligands for Target Protein for PROTAC	Cancer
A-1210477-piperazinyl is a compound binds to protein myeloid cell leukemia 1 (MCL1) used for PROTAC technology.

HY-111997

VH285-PEG4-C4-Cl HaloPROTAC 3	E3 Ligase Ligand-Linker Conjugates
VH285-PEG4-C4-Cl (HaloPROTAC 3) is a conjugate of ligands for E3 and 16-atom-length linker. The connector of linker is Halogen group. VH285-PEG4-C4-Cl incorporates the VH285 based VHL ligand and an alkyl/ether-based linker. VH285-PEG4-C4-Cl is a highly potent and efficacious degrader of GFP-HaloTag7 with a DC₅₀ of 19 nM. VH285-PEG4-C4-Cl is able to induce 90 % degradation of GFP-Halotag at 625 nM. VH285-PEG4-C4-Cl binds to VHL with an IC₅₀ of 0.54 μM.

HY-133927

(2E,6E)-3,7-Dimethyltrideca-2,6-dien-12-yn-1-ol
Others Others

(2E,6E)-3,7-Dimethyltrideca-2,6-dien-12-yn-1-ol is a isoprenoid analogue.

HY-151679

Fmoc-L-Lys(4-N3-Z)-OH	ADC Linker	Others
Fmoc-L-Lys(4-N3-Z)-OH is a click chemistry reagent containing an azide group. Fmoc-L-Lys(4-N3-Z)-OH acts as Lysine building-block for SPPS containing an Azide moiety as a bioorthogonal ligation handle, an infrared probe and a photo-affinity reagent. It can be decaged by trans-cyclooctenols via a strain-promoted 1,3-dipolar cycloaddition.

HY-126664

Azonafide-PEABA
ADC Cytotoxin Cancer

Azonafide-PEABA is a cytotoxic agent moiety.
HY-D1555

Cyanine7 DBCO
Cy7 DBCO
Fluorescent Dye Others

Cyanine7 DBCO is a water-soluble NIR fluorescent dye with cycloalkyne moiety.
HY-D1554

Cyanine5 tetrazine
Fluorescent Dye Others

Cyanine5 tetrazine, a fluorophore, is a molecule that contains a cyano5 fluorophore and a tetrazine moiety.

HY-107443

I-BET762 carboxylic acid Molibresib carboxylic acid; GSK525762A carboxylic acid; PROTAC BRD4-binding Moiety 2	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid (Molibresib carboxylic acid) is a BRD4 inhibitor with a pIC₅₀ of 5.1.

HY-119697

Setosusin
(+)-Setosusin
Endogenous Metabolite Others

Setosusin ((+)-Setosusin) is a fungal meroditerpenoid featuring a unique spiro-fused 3(2H)-furanone moiety.

HY-151754

DACN(Tos2,6-OH)	ADC Linker	Others
DACN(Tos2,6-OH) is a click chemistry reagent containing an Azide. The alkyne moiety within the ring has a unique bent structure and high reactivity toward cycloaddition reactions. The reactivity of an alkyne heavily depends on the electronic and steric characteristics of the substituents as well as structural strain. In comparison to nonbent acyclic alkynes, cyclononyne alkynes show remarkably high reactivity. Such strain-promoted azide-alkyne cycloadditions (SPAAC) using cycloalkynes have served for reliable molecular conjugation in a broad range of fields. The nitrogens are used as connection points for a variety of functional units. In comparison to cyclooctynes, DACNs possess high thermal and chemical stability along with comparable click reactivity.

HY-W441002

DSPE-succinic acid	Liposome	Others
DSPE-succinic acid is a phophalipid capped with a carboxylic acid moiety. The carboxylic acid moiety is reactive with amine to from a stable amide linkage. DSPE-succinic acid can be used to prepare nanoparticles or liposomes for agent nanocarrier to deliver therapeutics.

HY-P4108

TAT-HA2 Fusion Peptide	Influenza Virus	Others
TAT-HA2 Fusion Peptide is a peptide-based delivery agent that combines the pH-sensitive HA2 fusion peptide from Influenza and the cell-penetrating peptide TAT from HIV. TAT-HA2 Fusion Peptide induces the cellular uptake of macromolecules into endosomes via the TAT moiety and to respond to the acidifying lumen of endosomes to cause membrane leakage and release of macromolecules into cells via the HA2 moiety.

HY-146010

Carbonic anhydrase inhibitor 13	Carbonic Anhydrase	Cancer
Carbonic anhydrase inhibitor 13 (compound 7) is a potent carbonic anhydrase (CA) inhibitor, which features 3-methylthiazolo[3,2-a]benzimidazole moiety (as a tail) connected to the zinc anchoring benzenesulfonamide moiety via ureido linker.

HY-151769

TCO-PEG2-Sulfo-NHS ester-EDC Urea	ADC Linker	Others
TCO-PEG2-Sulfo-NHS ester-EDC Urea is a click chemistry reagent containing an azide group. TCO-PEG2-Sulfo-NHS ester is a PEG linker containing a TCO moiety and a sulfo-NHS ester moiety. The sulfo group makes this molecule soluble in waqueous buffer. This reagent can be used to label antibodies, proteins and other primary amine-containing macromolecules with TCO moiety. Reagent grade, for research use only.

HY-P2778

Ribonuclease H
RNase H
DNA/RNA Synthesis Others

Ribonuclease H is an enzyme degrading the RNA moiety of DNA-RNA hybrids.

HY-145663

HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM	Drug-Linker Conjugates for ADC	Cancer
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a agent-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety.

HY-16138

Ivaltinostat CG-200745	HDAC MDM-2/p53 Apoptosis	Cancer
Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects.

HY-17466

Sancycline Bonomycin; 6-Demethyl-6-deoxytetracycline	Bacterial Antibiotic	Infection
Sancycline is a rare semi-synthetic tetracycline prepared by hydrogenolysis of the chloro and benzylic hydroxy moieties of Declomycin.

HY-16138A

Ivaltinostat formic CG-200745 formic	HDAC MDM-2/p53 Apoptosis	Endocrinology Inflammation/Immunology
Ivaltinostat (CG-200745) formic is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat formic enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat formic induces apoptosis and has anti-tumour effects.

HY-146970

Lankacyclinone C
Antibiotic Cancer

Lankacyclinone C is a lankacidin C congener lacking the δ-lactone moiety, with antitumor activity.
HY-N1499

Nystose
Others Metabolic Disease

Nystose is a tetrasaccharide with two fructose molecules linked via beta (1→2) bonds to the fructosyl moiety of sucrose.
HY-107824

D-Melibiose
Endogenous Metabolite Inflammation/Immunology

D-Melibiose is a disaccharide which is composed of one galactose and one glucose moiety in an alpha (1-6) glycosidic linkage.
HY-D1071

DBCO-PEG12-TCO
Fluorescent Dye Others

DBCO-PEG12-TCO cantains a TCO and a DBCO moiety. TCO group can specifically react with terrahydrazine.

HY-100217

DL-3-Indolylglycine	Amino Acid Derivatives	Others
DL-3-Indolylglycine is an unnatural amino acid that is very similar to Tryptophan, with the indole moiety directly attached to the α-position.

HY-N11464

Kuwanon O
Others Others

Kuwanon O is a flavonoid derivative with a fused dihydrochalcone partial moiety, that can be isolated from the root bark of Morus lhou (set.) Koidz.

HY-143692

SQDG	Liposome	Metabolic Disease
SQDG is a glycolipid that possesses sugar moieties in their head groups. SQDG is a membrane lipid that can be used to investigate the effects of structural lipid in LNP formulations.

HY-111606

DUPA	Ligands for Target Protein for PROTAC	Cancer
DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in agent conjugate to selectively deliver cytotoxic agents to prostate cancer cells.

HY-D1510

4-Nitrophenyl 2-O-(β-L-Fucopyranosyl)-β-D-Galactopyranoside	Biochemical Assay Reagents	Others
4-Nitrophenyl 2-O-(β-L-Fucopyranosyl)-β-D-Galactopyranoside is a synthetic chromogenic substrate and can be used in the assay of α-fucosidases which hydrolyze the glycosidic linkage Fuc α1-2Gal. The assay is based on the sequential action of α-fucosidase and an exogenously added exo-β-d-galactosidase to release the easily measurable p-nitrophenol moiety.

HY-130080

DM3 Maytansinoid DM3	ADC Cytotoxin Microtubule/Tubulin	Cancer
DM3 (Maytansinoid DM3) is a maytansine analog bearing disulfide or thiol groups and a tubulin inhibitor, and is a cytotoxic moiety of antibody-drug conjugates (ADCs).

HY-100503

Maytansinoid DM4	ADC Cytotoxin	Cancer
Maytansinoid DM4 is a thiol-containing maytansine derivative with highly potent cytotoxicity. Maytansinoid DM4 can be used as a cytotoxic moiety of ADC.

HY-Y0015

p-Dimethylaminobenzaldehyde 4-Dimethylaminobenzaldehyde	Biochemical Assay Reagents	Others
p-Dimethylaminobenzaldehyde (4-Dimethylaminobenzaldehyde) is an organic compound containing amine and aldehyde moieties which is used in Ehrlich's reagent and Kovac's reagent to test for indoles.

HY-D1556

DOPE-CF	Fluorescent Dye	Others
DOPE-CF is a pH-sensitive fluorescent membrane labelled probe with a fluorescein moiety that is a weak acid and a conjugated base that is highly fluorescent and can be attached to phospholipid ethanolamine lipids.

HY-103591

DUPA(OtBu)-OH	Others	Cancer
DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

HY-W067056

Methyl (E)-cinnamate Methyl (E)-3-phenylpropenoate	Others	Inflammation/Immunology
Methyl (E)-cinnamate (EMC), a phytochemical constituent isolated from Alpinia katsumadai Hayata, is a natural flavor compound with anti-inflammatory properties. Methyl (E)-cinnamate is widely used in the food and commodity industry.

HY-41121

Boc-L-Ala-OH Boc-Ala-OH	Amino Acid Derivatives	Others
Boc-L-Ala-OH (Boc-Ala-OH) shows excellent affinity with ATP. Boc-L-Ala-OH contains an amino acid moiety, and an acylamide bond like that of the peptide and protein.

HY-101859

NucPE1 Nuclear Peroxy Emerald 1	Reactive Oxygen Species	Others
NucPE1 (Nuclear Peroxy Emerald 1) is a nuclear-localized fluorescent hydrogen peroxide that is specifically localized to cellular nuclei without appended targeting moieties. Storage: protect from light.

HY-150409

TSPO ligand-2	AUTACs	Cancer
TSPO ligand-2 is a ligand of AUTAC1. AUTAC1 contains an p-fluorobenzylguanine (FBnG) and a Fumagillol moiety, which can silence endogenous MetAP2 in HeLa cells.

HY-121597

Yuankanin	Others	Others
Yuankanin is a genkwanin-5-bioside, the sugar moiety being composed of xylose and glucose. Yuankanin can be isolated from the methanol extract of the aerial parts of Gnidia involucrata (Thymelaeaceae).

HY-130768

N-(Azido-PEG3)-N-Fluorescein-PEG3-acid	PROTAC Linkers	Cancer
N-(Azido-PEG3)-N-Fluorescein-PEG3-acid is a PEG-based PROTAC linker which contains azide, fluorescein and carboxylic acid moieties. Storage: protect from light.

HY-151789

Sulfo DBCO-TFP Ester	ADC Linker	Others
Sulfo DBCO-TFP Ester is a water-soluble, sulfo-containing click chemistry reagent. Sulfo DBCO-TFP Ester enables simple and efficient incorporation of sulfo-DBCO moieties onto amine-containing molecules.

HY-N6681

15-Acetoxyscirpenol	Caspase Bacterial Apoptosis Antibiotic	Infection
15-acetoxyscirpenol, one of acetoxyscirpenol moiety mycotoxins (ASMs), strongly induces apoptosis and inhibits Jurkat T cell growth in a dose-dependent manner by activating other caspases independent of caspase-3.

HY-130993

Isatropolone A	Parasite	Infection
Isatropolone A, a natural product containing a 1,5-diketone moiety, is reisolated from Streptomyces Gö66. Isatropolone A shows potent activity against *Leishmania donovani* with an IC₅₀ of 0.5 μM.

HY-P3362

Ac-IETD-AMC	Fluorescent Dye	Others
Ac-IETD-AMC is a fluorogenic caspase-8/granzyme B substrate containing the acetyl (Ac) moiety. Ac-IETD-AMC is frequently used to measure caspase-8 activity.

HY-135868

Mito-apocynin (C2)	Mitochondrial Metabolism	Neurological Disease
Mito-apocynin (C2), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP ⁺ cation. Mito-apocynin (C2) exhibits antineuroinflammatory effect.

HY-151645

Alkyne-SNAP	ADC Linker	Others
Alkyne-SNAP (compound 3) is an Alkyne-conjugated benzylguanine. The benzylguanine moiety reacts with the SNAP-tag, allowing irreversible and covalent labeling of SNAP fusion proteins with an additional alkyne functionality for further click chemistry conjugation.

HY-130581

Lipid X	Bacterial Antibiotic	Infection
Lipid X is a novel monosaccharide precursor of Lipid A (the active moiety of gram-negative endotoxin). Lipid X is protective against endotoxin administered to mice and sheep and against life-threatening gram-negative infections in mice.

HY-113123

LysoPC(14:0/0:0)	Endogenous Metabolite	Metabolic Disease Neurological Disease
LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. LysoPC(14:0/0:0) has potent antispasmodic effect.

HY-E70040

Endoglycoceramidase I (EGCase I)	Endogenous Metabolite	Metabolic Disease
Endoglycoceramidase I (EGCase I) is a glycosidase, is often used in biochemical studies. Endoglycoceramidase I catalyzes a transglycosylation reaction, which transfers the sugar moiety of GSLs to the primary hydroxyl group of several 1-alkanols.

HY-111839

ATRA-hydroxyimino CRABP-II ligand 1	Ligands for Target Protein for PROTAC	Cancer
ATRA-hydroxyimino (CRABP-II ligand 1), the Retinoic acid (ATRA)-based moiety, binds to cIAP1 ligand (Bestatin) via a linker to form SNIPER to degrade CRABP-II in IMR-32 cells.

HY-N8171

Lagotisoide D
10-O-[(E)-3,4-Dimethoxycinnamoyl]-catalpol
Others Others

Lagotisoide D is a lridoid glycoside from Lagotis yunnanensis.
HY-W127401

Triethylene glycol monooctyl ether
n-Octyltrioxyethylene
Biochemical Assay Reagents Others

Triethylene glycol monooctyl ether is a surfactant, C8E3 dissolves membrane proteins.

HY-144876

RIDR-PI-103	Reactive Oxygen Species	Cancer
RIDR-PI-103 is a reactive oxygen species (ROS)-induced drug release prodrug with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103).

HY-B1738

Pralidoxime	Cholinesterase (ChE)	Neurological Disease
Pralidoxime is a potent reactivator of acetylcholinesterase (AChE). Pralidoxime reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Pralidoxime is an antidote for organophosphate poisoning.

HY-B1200

Pralidoxime chloride 2-PAM chloride	Cholinesterase (ChE)	Neurological Disease
Pralidoxime chloride is a potent reactivator of acetylcholinesterase (AChE). Pralidoxime chloride reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Pralidoxime chloride is an antidote for organophosphate poisoning.

HY-150410

TSPO ligand-3	AUTACs	Cancer
TSPO ligand-3 is a ligand of AUTAC2. AUTAC2 contains an p-fluorobenzylguanine (FBnG) and an synthetic ligand of FKBP (SLF) moiety, which can cause significant silencing of FKBP12 in HeLa cells.

HY-134184

AUTAC2	AUTACs Autophagy	Cancer Inflammation/Immunology
AUTAC2 is a FKBP12-targeting autophagy-mediated degrader (AUTAC). AUTAC2 contains an FBnG (p-Fluorobenzyl Guanine) and an SLF (c ligand of FKBP) moiety. SLF binds non-covalently to FKBP12.

HY-129363

AP1867-3-(aminoethoxy)	Ligands for Target Protein for PROTAC FKBP	Cancer
AP1867-3-(aminoethoxy), the AP1867 based moiety, is a synthetic ligand for FKBP. AP1867-3-(aminoethoxy) can be used in the synthesis of PROTAC FKBP12 F36V degrader.

HY-W018772S6

D-Ribose-d	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-d is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gly

HY-134433

GDP-L-fucose	Endogenous Metabolite	Metabolic Disease
GDP-L-fucose is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides, providing the fucose moiety for the oligosaccharides.The formation of GDP-L-fucose occurs through two pathways, the major ab initio metabolic pathway and the minor remedial metabolic pathway.

HY-140345A

L-Homopropargylglycine hydrochloride	PROTAC Linkers	Cancer
L-Homopropargylglycine hydrochloride is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. L-homopropargylglycine hydrochloride is an amino acid analog of methionine containing an alkyne moiety that can undergo a classic click chemical reaction with azide containing Alexa Fluor.

HY-140345

L-Homopropargylglycine	PROTAC Linkers	Cancer
L-Homopropargylglycine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. L-homopropargylglycine is an amino acid analog of methionine containing an alkyne moiety that can undergo a classic click chemical reaction with azide containing Alexa Fluor.

HY-B1738A

Pralidoxime iodide	Cholinesterase (ChE)	Neurological Disease
Pralidoxime iodide is a potent reactivator of acetylcholinesterase (AChE). Pralidoxime iodide reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Pralidoxime iodide is an antidote for organophosphate poisoning.

HY-W018772S1

D-Ribose-13C	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-¹³C is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati

HY-W018772S

D-Ribose-18O	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-¹⁸O is the ¹⁸O labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati

HY-107447S

N-Deshydroxyethyl Dasatinib-d8	Ligands for Target Protein for PROTAC	Cancer
N-Deshydroxyethyl Dasatinib-d₈ is the deuterium labeled N-Deshydroxyethyl Dasatinib. N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL[1].

HY-W018772S9

D-Ribose-d-3	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-d-3 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g

HY-W018772S12

D-Ribose-d6	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-d₆ is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl

HY-W018772S10

D-Ribose-d2	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-d₂ is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl

HY-W018772S14

D-Ribose-d5	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-d₅ is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl

HY-115545

DBCO-NHS ester 3	ADC Linker	Cancer
DBCO-NHS ester 3 (Compound 12) is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 3 is a derivative of Dibenzylcyclooctyne (DBCO) obtained by activation of N-hydroxysuccinimide by the carboxylic acid moiety of both methyl-oxanorbornadiene (MeOND) and dibenzoazacyclooctyne (DIBAC).

HY-W018772S8

D-Ribose-d-2	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-d-2 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g

HY-W018772S7

D-Ribose-d-1	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-d-1 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g

HY-D1598

Sulfo-CY3 tetrazine potassium	Fluorescent Dye	Others
Sulfo-CY3 tetrazine potassium is a sulfo-Cyanine3 derivative that contains methyltetrazine moiety (Ex=548 nm, Em=563 nm). Sulfo-CY3 tetrazine potassium can be used for the labeling of metabolically engineered cell-surface glycoconjugates.

HY-P99770

Omodenbamab 514-G3	Bacterial	Infection
Omodenbamab is an anti-SpA (Staphylococcal protein A) humanized monoclonal antibody with a K_D value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection.

HY-134183

AUTAC1	AUTACs Autophagy	Cancer Metabolic Disease
AUTAC1 is a MetAP2-targeting autophagy-mediated degrader (AUTAC). AUTACs contain a degradation tag and a warhead to provide target specificity. AUTAC1 contains an FBnG (p-Fluorobenzyl Guanine) and a Fumagillol moiety. Fumagillol binds covalently to MetAP2.

HY-130994

Aeruginosin 865	NF-κB ADC Cytotoxin	Cancer Inflammation/Immunology
Aeruginosin 865, isolated from terrestrial cyanobacterium Nostoc sp. Lukešová 30/93, is the first aeruginosin-type peptide containing both a fatty acid and a carbohydrate moiety. Aeruginosin 865 inhibits translocation of NF-kB to the nucleus. Aeruginosin 865 has anti-inflammatory effect

HY-P3110

Ac-DNLD-AMC	Fluorescent Dye	Others
Ac-WLA-AMC is a fluorogenic substrate of caspase-3. Ac-WLA-AMC is cleaved to release the fluorescent moiety 7-amino-4-methylcoumarin (AMC), which can be used to quantify the β5c subunit activity.

HY-134433A

GDP-L-fucose disodium	Endogenous Metabolite	Metabolic Disease
GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway.

HY-W018772S2

D-Ribose-13C-1	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-¹³C-1 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-W018772S4

D-Ribose-13C-3	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-¹³C-3 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-151696

TCO-PEG3-maleimide	ADC Linker	Others
TCO-PEG3-maleimide (TCO-PEG3-NEM) is a click chemistry reagent. TCO-PEG3-maleimide efficiently binds TCO (trans-cyclooctene) moiety to thiol-containing molecules (such as antibodies, cysteine-containing peptides).

HY-D0152

Tetramethylrhodamine-6-maleimide	Fluorescent Dye	Others
Tetramethylrhodamine-6-maleimide is a fluorescent dye with a reactive sulfhydryl-specific moiety is covalently coupled to this cysteine. Tetramethylrhodamine-6-maleimide can be used as labels to detect local protein motions of the fully active Na+/K+-ATPase in real time.

HY-W018772S5

D-Ribose-13C-4	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-¹³C-4 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-W018772S3

D-Ribose-13C-2	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose-¹³C-2 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-W018772

D-Ribose(mixture of isomers)	Endogenous Metabolite	Inflammation/Immunology Cancer
D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner.

HY-112373

Aurora kinase inhibitor-3	Aurora Kinase	Others
Aurora kinase inhibitor-3 is a strong and selective Aurora A kinase inhibitor with an IC₅₀ of 42 nM, and weakly inhibits EGFR with an IC₅₀ of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket.

HY-B1497

Silver sulfadiazine AgSD	Bacterial DNA/RNA Synthesis Antibiotic	Infection
Silver sulfadiazine (AgSD), a sulfonamide antibiotic, effects a dual inhibitory action on bacterial growth by its sulfa moiety (SD-SDZ) that prevents bacterial folate absorption and subsequent DNA synthesis. The silver that is released from Silver sulfadiazine binds and disrupts the DNA structure, precluding bacterial DNA replication.

HY-D1557

Cyanine5.5 tetrazine	Fluorescent Dye	Others
Cyanine5.5 tetrazine is a far-infrared luminescent dye. Cyanine5.5 tetrazine is a Cyanine5.5 (HY-D0925A) derivative contains a tetrazine moiety. Cyanine5.5 tetrazine can be used for in vivo imaging and low background applications.

HY-136262

CRBN-6-5-5-VHL	PROTACs	Cancer
CRBN-6-5-5-VHL is a potent and selective von Hippel-Lindau-based cereblon (CRBN) degrader with a DC₅₀ value of 1.5 nM. CRBN-6-5-5-VHL has almost no effect on the degradation of the neo-substrates IKZF1 and IKZF3.

HY-147235

RIPK2-IN-2	RIP kinase PROTACs	Infection
RIPK2-IN-2 (example 25) is a RIP2 kinase PROTAC inhibitor. RIPK2-IN-2 can block RIP2-dependent proinflammatory signaling, regulated RIP2 kinase activity in auto inflammatory diseases.

HY-141481

DP-C-4
PROTACs EGFR PARP Cancer

DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP.

HY-P99225

Mirvetuximab M9346A	Antifolate	Cancer
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research.

HY-P99285

Denintuzumab hBU 12	ADC Antibody CD19	Others
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.

HY-141631

Dihomo-γ-Linolenoyl PAF C-16 L-α-Phosphatidylcholine	Biochemical Assay Reagents	Others
Dihomo-γ-Linolenoyl PAF C-16 is a PAF analog that contains dihomo-γ-linolenoate at the sn-2 position instead of the acetate moiety in PAF C-16. The biological activity of dihomo-γ-linolenoyl PAF C-16 is currently unknown but may be similar to that of arachidonoyl PAF C-16.

HY-100658

Didesmethyl cariprazine	5-HT Receptor Dopamine Receptor	Neurological Disease
Didesmethyl cariprazine is a metabolite of Cariprazine and acts as the predominant circulating active moiety. Didesmethyl cariprazine has a long half-life of 1-3 weeks. Cariprazine is a antipsychotic agent candidate that exhibits high affinity for the D₃ and D₂ receptors, and moderate affinity for the 5-HT_1A receptor.

HY-135869

Mito-apocynin (C11)	Mitochondrial Metabolism	Neurological Disease
Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP⁺ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function.

HY-W067056S1

Methyl(E)-cinnamate-d7 Methyl(E)-3-phenylpropenoate-d₇	Isotope-Labeled Compounds	Inflammation/Immunology
Methyl(E)-cinnamate-d₇ is the deuterium labeled Methyl (E)-cinnamate[1]. Methyl (E)-cinnamate (EMC), a phytochemical constituent isolated from Alpinia katsumadai Hayata, is a natural flavor compound with anti-inflammatory properties. Methyl (E)-cinnamate is widely used in the food and commodity industry[2].

HY-W067056S

Methyl (E)-cinnamate-d5 Methyl(E)-3-phenylpropenoate-d₅	Isotope-Labeled Compounds	Inflammation/Immunology
Methyl (E)-cinnamate-d₅ is the deuterium labeled Methyl (E)-cinnamate[1]. Methyl (E)-cinnamate (EMC), a phytochemical constituent isolated from Alpinia katsumadai Hayata, is a natural flavor compound with anti-inflammatory properties. Methyl (E)-cinnamate is widely used in the food and commodity industry[2].

HY-130081

DM3-SMe	ADC Cytotoxin Microtubule/Tubulin	Cancer
DM3-SMe is a maytansine derivative and a tubulin inhibitor, and is a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM3-SMe shows highly cytotoxic activity in vitro with an IC₅₀ of 0.0011 nM.

HY-W010970

5'-Guanylic acid disodium salt 5'-GMP disodium salt; 5'-guanosine monophosphate disodium salt	Endogenous Metabolite	Others
5'-Guanylic acid disodium salt (5'-GMP disodium salt) is composed of guanine, ribose, and phosphate moieties and it is a nucleotide monomer in messenger RNA. Guanosine derivatives are involved in intracellular signal transduction and have been identified in repetitive genomic sequences in telomeres, in ribosomal DNA, immunoglobulin heavy‐chain switch regions, and in the control regions of proto-oncogenes.

HY-138064

4-APC hydrobromide	Others	Others
4-APC hydrobromide is a highly sensitive and selective derivatization agent for aldehydes. 4-APC hydrobromide possesses an aniline moiety for a fast selective reaction with aliphatic aldehydes as well as a quaternary ammonium group for improved MS sensitivity. 4-APC hydrobromide allows highly sensitive and selective MS detection of aldehydes.

HY-D0146

Resorufin benzyl ether BzRes; 7-Benzyloxyresorufin; 7-Benzyloxyphenoxazone	Fluorescent Dye	Others
Resorufin benzyl ether (BzRes), a fluorogenic enzyme substrate, can be used to detect CYP3A4 enzyme activity. Resorufin benzyl ether modified with a recognizing moiety boronate, can be used for ONOO^- detection via a self-immolation mechanism. Ex/Em=530-570 nm/590 nm.

HY-130809

DBCO-PEG4-Biotin	Biochemical Assay Reagents	Cancer
DBCO-PEG4-Biotin is an azadibenzocyclooctyne-biotin derivative containing a biotin group and 4 PEGs. DBCO-PEG4-Biotin is a versatile biotinylation reagent used for the introduction of a biotin moiety to azide-labeled biomolecules via copper-free strain-promoted alkyne-azide click chemistry (SPAAC) reaction.

HY-130082

DM4-SMe	ADC Cytotoxin Microtubule/Tubulin	Cancer
DM4-SMe is a metabolite of antibody-maytansin conjugates (AMCs) and a tubulin inhibitor, and also a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM4-SMe inhibits KB cells with an IC₅₀ of 0.026 nM.

HY-75706

N-Descyclopropanecarbaldehyde Olaparib	E3 Ligase Ligand-Linker Conjugates PARP	Cancer
N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a CRBN-based ligand for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4. N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor.

HY-111518

JH-XI-10-02	PROTACs CDK	Cancer
JH-XI-10-02 is a PROTAC connected by ligands for Cereblon and CDK. JH-XI-10-02 is a highly potent and selective PROTAC CDK8 degrader, with an IC₅₀ of 159 nM. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19.

HY-147690

Photosensitizer-2	Others	Cancer
Photosensitizer-2 (compound 1) is a organic D-π-A sensitizer against phototoxicity. Photosensitizer-2 contains an acrylic acid moiety that exerts high levels of phototoxicity. Photosensitizer-2 shows antitumor activity against HeLa cells, with IC₅₀ values of 20.9 ± 4.5 μM (dark) and 0.046 ± 0.012 μM (irradiation), respectively.

HY-151697

DACN(Tos2)	ADC Linker	Others
DACN(Tos2) is a a click chemistry reagent containing an cycloalkynes group. The alkyne moiety within the ring has a unique bent structure and high reactivity toward cycloaddition reactions. DACN(Tos2) through such strain-promoted azide-alkyne cycloadditions (SPAAC) using cycloalkynes. DACN(Tos2) can be used for the research of molecular conjugation.

HY-N10800

1,2,6,7,8,9-Hexahydro-1,6,6-trimethyl-3,11-dioxanaphth[2,1-e]azulene-10,12-dione	Others	Cancer
1,2,6,7,8,9-Hexahydro-1,6,6-trimethyl-3,11-dioxanaphth[2,1-e]azulene-10,12-dione is a kind of chemical constituents of Salvia miltiorrhiza f. alba. The dihydroisotanshinone with a para-quinone moiety shows cytotoxicity and anti-tumor activity.

HY-111024

2,2,5,7,8-Pentamethyl-6-Chromanol PMC	Androgen Receptor	Cancer
2,2,5,7,8-Pentamethyl-6-Chromanol (PMC) is the anti-oxidant moiety of vitamin E (α-tocopherol). 2,2,5,7,8-Pentamethyl-6-Chromanol has potent androgen receptor (AR) signaling modulation and anti-cancer activity against prostate cancer cell lines.

HY-151795

DACN(Tos) hydrochloride	ADC Linker	Others
DACN(Tos) hydrochloride is a click chemistry reagent containing a cycloalkyne group. The alkyne moiety within the ring has a unique bent structure and high reactivity toward cycloaddition reactions, such strain-promoted azide-alkyne cycloadditions (SPAAC) by using cycloalkynes. DACNs possess high thermal and chemical stability along with comparable click reactivity. DACN(Tos) hydrochloride can be used for the research of molecular conjugation.

HY-145969

β-S-ARCA	Others	Others
β-S-ARCA is a mRNA 7-methylguanosine (m⁷G) cap analog carrying a phosphorothioate (PS) moiety. mRNAs incorporating β-S-ARCA have elongated cellular half-lives and showed augmented protein expression. β-S-ARCA D1 has been applied in researching experimental mRNA-based anticancer vaccines.

HY-151646

Alkyne-PEG5-SNAP	ADC Linker	Others
Alkyne-PEG5-SNAP is a click chemistry reagent containing an alkyne group. Alkyne-PEG5-SNAP can alkyne conjugated benzylguanine (BG), the BG moiety reacts specifically and rapidly with SNAP-tag, a polypeptide protein tag, allowing irreversible and covalent labeling of SNAP fusion proteins with an additional alkyne functionality suitable for further conjugation.

HY-119726

Fosmanogepix APX001; E1211	Fungal	Infection
Fosmanogepix (APX001) is a first-in-class and orally available broad-spectrum antifungal agent, which targets the highly conserved Gwt1 fungal enzyme. Fosmanogepix (APX001) is an N-phosphonooxymethyl prodrug which is rapidly and completely metabolized by systemic alkaline phosphatases to the active moiety, APX001A. Fosmanogepix (APX001) can be used in development for the treatment of invasive fungal infections.

HY-146489

Anti-infective agent 3	Bacterial Parasite	Infection
Anti-infective agent 3 (compound 3l) shows antiparasitic activity against P. falciparum and T. brucei rhodesiense, with IC₅₀ values of 0.47 and 0.13 μM, respectively. Anti-infective agent 3 shows antimycobacterial activity against Mycobacterium smegmatis with a MIC of 4 μg/mL.

HY-107767

Antibiotic DC 81 DC 81	Antibiotic Apoptosis DNA/RNA Synthesis	Cancer
Antibiotic DC 81 (DC 81), an antitumor antibiotic produced by Streptomyces species, is a PBD (pyrrolo[2,1-c][1,4]benzodiazepine). Antibiotic DC 81 is potent inhibitor of nucleic acid synthesis. Antibiotic DC 81 can recognize and bind to specific sequences of DNA and form a labile covalent adduct.

HY-141147

7-O-(Amino-PEG4)-paclitaxel	Drug-Linker Conjugates for ADC	Cancer
7-O-(Amino-PEG4)-paclitaxel is a PEG-class Drug-linker conjugates for ADC, containing a paclitaxel moiety and a amino group. The amine group is reactive with carboxylic acids, activated NHS esters, carbonyls (ketone, aldehyde) etc. 7-O-(Amino-PEG4)-paclitaxel can be used in the synthesis of Antibody-Drug Conjugates (ADCs).

HY-D1636

5-Nitro BAPTA	Fluorescent Dye	Others
5-Nitro BAPTA is a calcium chelator, combinded with 2-Me-substituted TM ( as a fluorescent moiety), can be used to form a red fluorescent probe (CaTM-2 AM), for imaging of cytoplasmic Ca²⁺ in cultured living cells. 5-Nitro BAPTA is a building block used in the synthesis of Ca²⁺ specific chelators, Ca²⁺ buffers, and fluorescent Ca²⁺ indicators.

HY-150408

FBnG-(Cys-acetamide)-CH2-PEG3-CH2-CH2-CH2-NH2	AUTACs	Cancer
FBnG-(Cys-acetamide)-CH2-PEG3-CH2-CH2-CH2-NH2 is a linker of AUTAC4. AUTAC4 contains an p-fluorobenzylguanine (FBnG) and a phenylindole moiety, which can induce K63-linked polyubiquitination and degradation of mitochondria in HeLa cells.

HY-140015

TCO-PEG3-acid
PROTAC Linkers Cancer

TCO-PEG3-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141178

TCO-PEG3-amine
PROTAC Linkers Cancer

TCO-PEG3-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141181

TCO-PEG8-amine
PROTAC Linkers Cancer

TCO-PEG8-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

HY-W087383

Thalidomide 5-fluoride	Ligands for E3 Ligase	Cancer
Thalidomide 5-fluoride is Thalidomide-based cereblon ligand that incorporates to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1.

HY-133049

Propargyl-PEG3-phosphonic acid
PROTAC Linkers Cancer

Propargyl-PEG3-phosphonic acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130146

Propargyl-PEG3-phosphonic acid diethyl ester
PROTAC Linkers Cancer

Propargyl-PEG3-phosphonic acid diethyl ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130382

Propargyl-PEG6-alcohol
PROTAC Linkers Cancer

Propargyl-PEG6-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-121507

Hydroxy-PEG2-C2-sulfonic acid
PROTAC Linkers Cancer

Hydroxy-PEG2-C2-sulfonic acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

HY-123109

(S,R,S)-AHPC-Boc VH032-Boc	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Boc (VH032-Boc) is a ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Boc is used in PROTAC technology.

HY-130554

m-PEG9-phosphonic acid
PROTAC Linkers Cancer

m-PEG9-phosphonic acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141187

TCO-PEG3-TCO
PROTAC Linkers Cancer

TCO-PEG3-TCO is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-41921

Propargyl-PEG3-alcohol
PROTAC Linkers Cancer

Propargyl-PEG3-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130390

Propargyl-PEG4-O-C1-NHS ester
PROTAC Linkers Cancer

Propargyl-PEG4-O-C1-NHS ester (compound 8) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141159

TCO-PEG4-acid
PROTAC Linkers Cancer

TCO-PEG4-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141166

TCO-PEG3-NHS ester
PROTAC Linkers Cancer

TCO-PEG3-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-133230

Propargyl-PEG10-amine
PROTAC Linkers Cancer

Propargyl-PEG10-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130563

Propargyl-PEG3-CH2COOH
PROTAC Linkers Cancer

Propargyl-PEG3-CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-112559

Bis-PEG2-acid
PROTAC Linkers Cancer

Bis-PEG2-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141160

TCO-PEG6-acid
PROTAC Linkers Cancer

TCO-PEG6-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-115414

Bis-propargyl-PEG8
PROTAC Linkers Cancer

Bis-propargyl-PEG8 (compound 16e) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130147

Propargyl-PEG5-OH
PROTAC Linkers Cancer

Propargyl-PEG5-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141161

TCO-PEG8-acid
PROTAC Linkers Cancer

TCO-PEG8-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141183

TCO-PEG4-biotin
PROTAC Linkers Cancer

TCO-PEG4-biotin is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130374

Propargyl-PEG8-OH
PROTAC Linkers Cancer

Propargyl-PEG8-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-133229

Propargyl-PEG4-alcohol
PROTAC Linkers Cancer

Propargyl-PEG4-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130137

m-PEG8-C10-phosphonic acid
PROTAC Linkers Cancer

m-PEG8-C10-phosphonic acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141180

TCO-PEG6-amine
PROTAC Linkers Cancer

TCO-PEG6-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130389

Propargyl-PEG4-O-C1-Boc
PROTAC Linkers Cancer

Propargyl-PEG4-O-C1-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130375

Propargyl-PEG8-Boc
PROTAC Linkers Cancer

Propargyl-PEG7-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-117045

Propargyl-PEG12-OH
PROTAC Linkers Cancer

Propargyl-PEG12-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-126977

Propargyl-PEG9-OH
PROTAC Linkers Cancer

Propargyl-PEG9-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141189

TCO-PEG8-TCO
PROTAC Linkers Cancer

TCO-PEG8-TCO is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141179

TCO-PEG4-amine
PROTAC Linkers Cancer

TCO-PEG4-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-120587

Bis-PEG6-acid
PROTAC Linkers Cancer

Bis-PEG6-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141177

TCO-PEG2-amine
PROTAC Linkers Cancer

TCO-PEG2-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-126891

Bis-PEG3-acid
PROTAC Linkers Cancer

Bis-PEG3-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141169

TCO-PEG8-NHS ester
PROTAC Linkers Cancer

TCO-PEG8-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130378

Propargyl-PEG7-alcohol
PROTAC Linkers Cancer

Propargyl-PEG7-alcohol is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130584

Propargyl-PEG2-Ms
PROTAC Linkers Cancer

Propargyl-PEG2-Ms is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-114670

Propargyl-PEG4-amine
PROTAC Linkers Cancer

Propargyl-PEG4-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141162

TCO-PEG12-acid
PROTAC Linkers Cancer

TCO-PEG12-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130373

Propargyl-PEG9-amine
PROTAC Linkers Cancer

Propargyl-PEG9-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130819

Tos-PEG4-THP
PROTAC Linkers Cancer

Tos-PEG4-THP is a PEG-based PROTAC linker can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523).
HY-130380

Propargyl-PEG7-Boc
PROTAC Linkers Cancer

Propargyl-PEG7-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-130384

Propargyl-PEG6-Boc
PROTAC Linkers Cancer

Propargyl-PEG6-Boc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141188

TCO-PEG4-TCO
PROTAC Linkers Cancer

TCO-PEG4-TCO is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-113921

m-PEG4-propargyl
PROTAC Linkers Cancer

m-PEG4-propargyl is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
HY-141168

TCO-PEG6-NHS ester
PROTAC Linkers Cancer

TCO-PEG6-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

HY-N9448

Lacto-N-tetraose	Bacterial	Infection Inflammation/Immunology
Lacto-N-tetraose is the significant core structure of human milk oligosaccharides (HMOs) naturally existing in human milk. Lacto-N-tetraose is consist of galactose, N-acetylglucosamine, and glucose moieties. Lacto-N-tetraose has prebiotic effect, immune regulatory effect, anti-inflammatory effects, intestinal cell responses regulatory effect, antibacterial activity and antiviral activity. Lacto-N-tetraose has been widely added to infant formula.

HY-141148

7-O-(Cbz-N-amido-PEG4)-paclitaxel	Drug-Linker Conjugates for ADC	Cancer
7-O-(Cbz-N-amido-PEG4)-paclitaxel is a PEG-class Drug-linker conjugates for ADC, containing a paclitaxel moiety and a amino group. The amine group is reactive with carboxylic acids, activated NHS esters, carbonyls (ketone, aldehyde) etc. 7-O-(Cbz-N-amido-PEG4)-paclitaxel can be used in the synthesis of Antibody-Drug Conjugates (ADCs).

HY-151761

H-L-Lys(4-N3-Z)-OH hydrochloride	ADC Linker	Others
H-L-Lys(4-N3-Z)-OH hydrochloride is a click chemistry reagent containing an azide group. H-L-Lys(4-N3-Z)-OH hydrochloride contains a lysine-modified azide moiety and as a bioorthogonal ligation handle. H-L-Lys(4-N3-Z)-OH hydrochloride is an infrared probe and a photo-affinity reagent.

HY-146488

Anti-infective agent 2	Parasite Bacterial	Infection
Anti-infective agent 2 (compound 3k) shows antiparasitic activity against P. falciparum and T. brucei rhodesiense, with IC₅₀ values of 0.07 and 2.20 μM, respectively. Anti-infective agent 2 shows antimycobacterial activity against Mycobacterium smegmatis with a MIC of 32 μg/mL.

HY-146487

Anti-infective agent 1	Bacterial Parasite	Infection
Anti-infective agent 1 (compound 3a) is a potent and selective antiprotozoal and antimycobacterial agent. Anti-infective agent 1 shows antiparasitic activity against P. falciparum and T. brucei rhodesiense, with IC₅₀ values of 10.95 and 0.06 μM, respectively. Anti-infective agent 1 shows antimycobacterial activity against Mycobacterium smegmatis with a MIC of 8 μg/mL.

HY-E70064

alpha-1,3-Fucosyltransferase (α1,3FucT)	Endogenous Metabolite	Others
alpha-1,3-Fucosyltransferase (α1,3FucT) catalyzes the transfer of L-fucose moiety from guanosine diphosphate-beta-L-fucose (GDP-Fuc) to acceptor sugars. alpha-1,3-Fucosyltransferase (α1,3FucT) is often used in biochemical studies, and it can be used to form fucoglycoconjugates.

HY-W018772S15

D-Ribose(mixture of isomers)-13c5	Endogenous Metabolite
D-Ribose(mixture of isomers)-¹³C₅ isomers)-¹³C₅ is the ¹³C labeled D-Ribose(mixture of isomers)[1]. D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner[1].

HY-151822

Hydroxy-PEG3-DBCO	ADC Linker	Others
Hydroxy-PEG3-DBCO is a click chemistry reagent containing an azide group. Hydroxy-PEG3-DBCO is a PEG linker containing a DBCO moiety and a terminal primary hydroxyl group. The hydroxyl can react with a variety of functional groups and the hydrophilic PEG spacer arm can provide better solubility to labeled molecules. DBCO is commonly used for copper-free Click Chemistry reactions. Reagent grade, for research use only.

HY-129379

DC0-NH2	ADC Cytotoxin	Cancer
DC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by alkylation of adenine residues by its propabenzindole (CBI) component.

HY-P2869

β-Galactosidase	Endogenous Metabolite	Others
β-Galactosidase is a glycoside hydrolase that hydrolyzes the β-glycosidic bonds formed between galactose and its organic moieties. In E.coli, the lacZ gene is the structural gene of β-galactosidase, which can be used as part of the induction system lac operon. β-Galactosidase can hydrolyze lactose to form glucose and galactose, and enter glycolysis; it can also catalyze the transgalactosylation of lactose into allolactose; allolactose can be cracked into monosaccharides.

HY-151766

DACN(Tos,Suc-OH)	ADC Linker	Others
DACN(Tos,Suc-OH) is a click chemistry reagent containing a cycloalkyne group. The alkyne moiety within the ring has a unique bent structure and high reactivity toward cycloaddition reactions. Such strain-promoted azide-alkyne cycloadditions (SPAAC) using cycloalkynes have served for reliable molecular conjugation in a broad range of fields. The nitrogens are used as connection points for a variety of functional units. DACNs possess high thermal and chemical stability along with comparable click reactivity.

HY-N3513

Mulberrin Kuwanon C	Others	Cardiovascular Disease
Mulberrin is a strong inhibitor of organic anion-transporting polypeptide 2B1 (OATP2B1)-mediated estrone-3-sulfate (E3S) uptake with an IC₅₀ value being 1.8 ±1.5 μM.

HY-139659

ARD-61	PROTACs Androgen Receptor Progesterone Receptor Apoptosis	Cancer
ARD-61 is a highly potent, effective and specific PROTAC androgen receptor (AR) degrader. ARD-61 potently and effectively induces AR and progesterone receptors (PR) degradation in AR+ cancer cell lines. ARD-61 induces apoptosis and effectively induces tumor growth inhibition in the MDA-MB-453 xenograft model in mice.

HY-N10527

Isoglobotetraose Globoisotetraose	Others	Others
Isoglobotetraose (Globoisotetraose) is the oligosaccharide moiety of human glycosphingolipids. Synthesis process: globotetraose (GalNAcβ1→3Galα1→4Galβ1→4Glc) and isoglobotetraose (GalNAcβ1→3Galα1→3Galβ1→4Glc).

HY-76779

4-(Chloromethyl)-7-hydroxycoumarin	Others	Cancer
4-(Chloromethyl)-7-hydroxycoumarin (compound 4) is a hydroxycoumarin derivative with potent antioxidant effect and high hydroxyl radical-scavenging property. 4-(Chloromethyl)-7-hydroxycoumarin contains a methyl group and a chlorine group in the heterocyclic ring. A series of coumarins incorporating hydroxy-, chloro- and/or chloromethyl-moieties has been investigated as potent inhibitors of the zinc enzyme carbonic anhydrase, expecially tumor-associated isoforms CA IX and XII.

HY-N10577

Chlorfortunone A	TGF-beta/Smad	Cancer
Chlorfortunone A is a novel sesquiterpenoid dimers, can be isolated from the roots of Chloranthus fortunei. Chlorfortunone A inhibits transforming growth factor (TGF)-β activity.

HY-140902A

Biotin-PEG3-C3-NH2
PROTAC Linkers Cancer

Biotin-PEG3-C3-NH2 is a PEG-based PROTAC linker, with NH₂ functional group, that can be used in the synthesis of PROTACs.
HY-145514A

dTAGV-1-NEG
PROTACs FKBP Cancer

dTAGV-1-NEG is a diastereomer and as a heterobifunctional negative control of dTAGV-1. dTAGV-1 is an FKBP12^F36V-selective degrader.
HY-145514B

dTAGV-1-NEG TFA
FKBP PROTACs Cancer

dTAGV-1-NEG TFA is a diastereomer and as a heterobifunctional negative control of dTAGV-1. dTAGV-1-NEG TFA is an FKBP12^F36V-selective degrader.

HY-130410

Bis-PEG6-NHS ester	ADC Linker PROTAC Linkers	Cancer
Bis-PEG6-NHS ester is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG6-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-126885

DBCO-PEG5-NHS ester	ADC Linker PROTAC Linkers	Cancer
DBCO-PEG5-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. DBCO-PEG5-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-126892

Bis-PEG7-acid	PROTAC Linkers ADC Linker	Cancer
Bis-PEG7-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG6-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-130408

m-PEG6-Amine	ADC Linker PROTAC Linkers	Cancer
m-PEG6-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG6-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-W018174

m-PEG3-Amine	ADC Linker PROTAC Linkers	Cancer
m-PEG3-Amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. m-PEG3-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-130387

Propargyl-PEG4-Tos	PROTAC Linkers ADC Linker	Cancer
Propargyl-PEG4-Tos is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG4-Tos is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-126894

Bis-PEG9-acid	PROTAC Linkers ADC Linker	Cancer
Bis-?PEG9-?acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-?PEG9-?acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-118808

Propargyl-PEG2-NHBoc	ADC Linker PROTAC Linkers	Cancer
Propargyl-PEG2-NHBoc is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-NHBoc is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

HY-126976

Propargyl-PEG5-amine	ADC Linker PROTAC Linkers	Cancer
Propargyl-PEG5-amine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG5-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

HY-126893

Bis-PEG8-acid	PROTAC Linkers ADC Linker	Cancer
Bis-PEG8-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Bis-PEG8-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-140310

TCO-PEG4-DBCO	ADC Linker PROTAC Linkers	Cancer
TCO-PEG4-DBCO is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. TCO-PEG4-DBCO is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

HY-W051634

Propargyl-PEG2-amine	ADC Linker PROTAC Linkers	Cancer
Propargyl-PEG2-amine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG2-amine is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

HY-129937A

GNE-987	PROTACs Epigenetic Reader Domain	Cancer
GNE-987 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. GNE-987 exhibits picomolar cell BRD4 degradation activity (DC₅₀=0.03 nM for EOL-1 AML cell line). GNE-987 binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC₅₀=4.7 and 4.4 nM, respectively). GNE-987 incorporates a potent BET binder/inhibitor, a VHL-binding fragment, and a ten methylene spacer moiety. GNE-987 can be used in PROTAC-Antibody Conjugate (PAC).

HY-134417

NSC2805
Others Cancer

NSC2805 is a WWP2 ubiquitin ligase inhibitor that can significant inhibit WWP2 activity with an IC₅₀ of 0.38 μM. NSC2805 can be used for the research of cancer.

HY-112077

13-cis-N-[4-(Ethoxycarbonyl)phenyl]retinamide Ethyl 4-((2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamido)benzoate	Others	Inflammation/Immunology
13-cis-N-[4-(Ethoxycarbonyl)phenyl]retinamide is a derivative of Retinoic acid.

Cat. No.	Product Name

HY-L128

E3 Ligase Ligand Library

48 compounds

Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).

MCE carefully prepared a unique collection of 48 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

HY-L050

Ubiquitination Compound Library

226 compounds

Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc.

MCE offers a unique collection of 226 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

HY-L129

Target Protein Ligand Library

34 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 34 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

HY-L045

Oxygen Sensing Compound Library

2051 compounds

Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression.

Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival.

HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation.

MCE offers a unique collection of 2051 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

HY-L137

Molecular Glue Compound Library

37 Compounds compounds

Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention.

Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy.

MCE supplies a unique collection of 37 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

Cat. No.	Product Name	Type

HY-D1555

Cyanine7 DBCO
Cy7 DBCO
Fluorescent Dyes/Probes

Cyanine7 DBCO is a water-soluble NIR fluorescent dye with cycloalkyne moiety.
HY-D1071

DBCO-PEG12-TCO
Dyes

DBCO-PEG12-TCO cantains a TCO and a DBCO moiety. TCO group can specifically react with terrahydrazine.

HY-D1556

DOPE-CF	Fluorescent Dyes/Probes
DOPE-CF is a pH-sensitive fluorescent membrane labelled probe with a fluorescein moiety that is a weak acid and a conjugated base that is highly fluorescent and can be attached to phospholipid ethanolamine lipids.

HY-101859

NucPE1 Nuclear Peroxy Emerald 1	Fluorescent Dyes/Probes
NucPE1 (Nuclear Peroxy Emerald 1) is a nuclear-localized fluorescent hydrogen peroxide that is specifically localized to cellular nuclei without appended targeting moieties. Storage: protect from light.

HY-130768

N-(Azido-PEG3)-N-Fluorescein-PEG3-acid	Fluorescent Dyes/Probes
N-(Azido-PEG3)-N-Fluorescein-PEG3-acid is a PEG-based PROTAC linker which contains azide, fluorescein and carboxylic acid moieties. Storage: protect from light.

HY-P3362

Ac-IETD-AMC	Fluorescent Dyes/Probes
Ac-IETD-AMC is a fluorogenic caspase-8/granzyme B substrate containing the acetyl (Ac) moiety. Ac-IETD-AMC is frequently used to measure caspase-8 activity.

HY-D1598

Sulfo-CY3 tetrazine potassium	Fluorescent Dyes/Probes
Sulfo-CY3 tetrazine potassium is a sulfo-Cyanine3 derivative that contains methyltetrazine moiety (Ex=548 nm, Em=563 nm). Sulfo-CY3 tetrazine potassium can be used for the labeling of metabolically engineered cell-surface glycoconjugates.

HY-P3110

Ac-DNLD-AMC	Dyes
Ac-WLA-AMC is a fluorogenic substrate of caspase-3. Ac-WLA-AMC is cleaved to release the fluorescent moiety 7-amino-4-methylcoumarin (AMC), which can be used to quantify the β5c subunit activity.

HY-D0152

Tetramethylrhodamine-6-maleimide	Fluorescent Dyes/Probes
Tetramethylrhodamine-6-maleimide is a fluorescent dye with a reactive sulfhydryl-specific moiety is covalently coupled to this cysteine. Tetramethylrhodamine-6-maleimide can be used as labels to detect local protein motions of the fully active Na+/K+-ATPase in real time.

HY-D1557

Cyanine5.5 tetrazine	Fluorescent Dyes/Probes
Cyanine5.5 tetrazine is a far-infrared luminescent dye. Cyanine5.5 tetrazine is a Cyanine5.5 (HY-D0925A) derivative contains a tetrazine moiety. Cyanine5.5 tetrazine can be used for in vivo imaging and low background applications.

Cat. No.	Product Name	Type

HY-W012845A

*(E)-3-(2-Furyl)acrolein*	Biochemical Assay Reagents
(E)-3-(2-Furyl)acrolein is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-P2778

Ribonuclease H
RNase H
Enzyme

Ribonuclease H is an enzyme degrading the RNA moiety of DNA-RNA hybrids.

HY-143692

SQDG	LNPs for Drug Delivery
SQDG is a glycolipid that possesses sugar moieties in their head groups. SQDG is a membrane lipid that can be used to investigate the effects of structural lipid in LNP formulations.

HY-E70040

Endoglycoceramidase I (EGCase I)	Enzyme
Endoglycoceramidase I (EGCase I) is a glycosidase, is often used in biochemical studies. Endoglycoceramidase I catalyzes a transglycosylation reaction, which transfers the sugar moiety of GSLs to the primary hydroxyl group of several 1-alkanols.

HY-W127401

Triethylene glycol monooctyl ether
n-Octyltrioxyethylene
Biochemical Assay Reagents

Triethylene glycol monooctyl ether is a surfactant, C8E3 dissolves membrane proteins.

HY-134433A

GDP-L-fucose disodium	Biochemical Assay Reagents
GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway.

HY-141631

Dihomo-γ-Linolenoyl PAF C-16 L-α-Phosphatidylcholine	Biochemical Assay Reagents
Dihomo-γ-Linolenoyl PAF C-16 is a PAF analog that contains dihomo-γ-linolenoate at the sn-2 position instead of the acetate moiety in PAF C-16. The biological activity of dihomo-γ-linolenoyl PAF C-16 is currently unknown but may be similar to that of arachidonoyl PAF C-16.

HY-E70064

alpha-1,3-Fucosyltransferase (α1,3FucT)	Enzyme
alpha-1,3-Fucosyltransferase (α1,3FucT) catalyzes the transfer of L-fucose moiety from guanosine diphosphate-beta-L-fucose (GDP-Fuc) to acceptor sugars. alpha-1,3-Fucosyltransferase (α1,3FucT) is often used in biochemical studies, and it can be used to form fucoglycoconjugates.

HY-P2869

β-Galactosidase

Enzyme

β-Galactosidase is a glycoside hydrolase that hydrolyzes the β-glycosidic bonds formed between galactose and its organic moieties. In E.coli, the lacZ gene is the structural gene of β-galactosidase, which can be used as part of the induction system lac operon. β-Galactosidase can hydrolyze lactose to form glucose and galactose, and enter glycolysis; it can also catalyze the transgalactosylation of lactose into allolactose; allolactose can be cracked into monosaccharides.

Cat. No.	Product Name	Target	Research Area

HY-P1348

*GLP-1 moiety* from Dulaglutide**	GCGR	Metabolic Disease
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.

HY-P4108

TAT-HA2 Fusion Peptide	Influenza Virus	Others
TAT-HA2 Fusion Peptide is a peptide-based delivery agent that combines the pH-sensitive HA2 fusion peptide from Influenza and the cell-penetrating peptide TAT from HIV. TAT-HA2 Fusion Peptide induces the cellular uptake of macromolecules into endosomes via the TAT moiety and to respond to the acidifying lumen of endosomes to cause membrane leakage and release of macromolecules into cells via the HA2 moiety.

HY-41121

Boc-L-Ala-OH Boc-Ala-OH	Amino Acid Derivatives	Others
Boc-L-Ala-OH (Boc-Ala-OH) shows excellent affinity with ATP. Boc-L-Ala-OH contains an amino acid moiety, and an acylamide bond like that of the peptide and protein.

HY-P3362

Ac-IETD-AMC	Fluorescent Dye	Others
Ac-IETD-AMC is a fluorogenic caspase-8/granzyme B substrate containing the acetyl (Ac) moiety. Ac-IETD-AMC is frequently used to measure caspase-8 activity.

HY-W141932

N-Stearoylglycine Stearoylglycine; N-Octadecanoylglycine	Peptides	Others
N-stearoylglycine is a lipid and has a small ionizable polar headgroup whose charge is pH dependent and whose amide moiety can form H-bonded network between adjacent molecules in ordered films.

HY-P3110

Ac-DNLD-AMC	Fluorescent Dye	Others
Ac-WLA-AMC is a fluorogenic substrate of caspase-3. Ac-WLA-AMC is cleaved to release the fluorescent moiety 7-amino-4-methylcoumarin (AMC), which can be used to quantify the β5c subunit activity.

Cat. No.	Product Name	Target	Research Area

HY-P9934

Abciximab C7E3	Integrin	Cardiovascular Disease
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.

HY-P99770

Omodenbamab 514-G3	Bacterial	Infection
Omodenbamab is an anti-SpA (Staphylococcal protein A) humanized monoclonal antibody with a K_D value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection.

HY-P99225

Mirvetuximab M9346A	Antifolate	Cancer
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research.

HY-P99285

Denintuzumab hBU 12	ADC Antibody CD19	Others
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.

Cat. No.	Product Name	Target	Category

HY-N8096

Raddeanoside R17 Pulchinenoside E3	Others	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Ranunculaceae Pulsatilla cernua (Thunb.) Bercht. et Opiz.
Raddeanoside R17 (Pulchinenoside E3) is a saponin compound that can be isolated from the root of Pulsatilla koreana. Raddeanoside R17 shows anti-inflammatory effects.

HY-N0170

Indole-3-carbinol I3C; 3-Indolemethanol	NF-κB Aryl Hydrocarbon Receptor E1/E2/E3 Enzyme Endogenous Metabolite	Indole Alkaloids Alkaloids Disease Research Fields Cancer Classification of Application Fields Source classification Plants other families Endogenous metabolite
Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).

HY-W068771

*(E)-3-(4-Methoxyphenyl)acrylic acid*	Endogenous Metabolite	Phenylpropanoids Structural Classification Simple Phenylpropanols other families Plants Source classification
(E)-3-(4-Methoxyphenyl)acrylic acid (compound 3) is isolated from Arachis hypogaea, Scrophularia buergeriana Miquel, Aquilegia vulgaris, Anigozanthos preissii and so on. (E)-3-(4-Methoxyphenyl)acrylic acid shows significant hepatoprotective activity, anti-amnesic, cognition-enhancing activity, antihyperglycemic, and neuroprotective activities.

HY-N1414

*(E)-3',6-Disinapoylsucrose*	Others	Phenylpropanoids Simple Phenylpropanols Phenols Polyphenols Source classification Plants Polygalaceae Polygala tenuifolia Willd.
(E)-3',6-Disinapoylsucrose, the index component of Yuanzhi (Polygala tenuifolia Willd), possesses potent antioxidant activity and antidepressant effect.

HY-W068783

*(E)-3,4-(Methylenedioxy)cinnamic acid* (E)-Piperonylprop-2-enoic acid	Endogenous Metabolite	Ketones, Aldehydes, Acids Structural Classification
(E)-3,4-(Methylenedioxy)cinnamic acid is a cinnamic acid derivative obtained from the stem bark of Brombya platynema.

HY-N11650

(22S,24E)-3β,22-Diacetoxylanosta-7,9(11),24-trien-26-oic acid	Bacterial	Triterpenes Structural Classification Terpenoids Microorganisms Source classification
(22S,24E)-3β,22-Diacetoxylanosta-7,9(11),24-trien-26-oic acid (compound 15) is an antitubercular agent with MIC value of 12.5 μg/mL for Mycobacterium tuberculosis H37Ra. (22S,24E)-3β,22-Diacetoxylanosta-7,9(11),24-trien-26-oic acid shows cytotoxicity with IC₅₀ value of 32 μM for Vero cells.

HY-N1778A

*(E)-3,4-Dimethoxycinnamic acid* (E)-O-Methylferulic acid	Reactive Oxygen Species Virus Protease	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Infection Source classification Plants other families
(E)-3,4-Dimethoxycinnamic acid is the less active isomer of 3,4-Dimethoxycinnamic acid. 3,4-Dimethoxycinnamic acid exerts anti-apoptotic effects on L-02 cells via the ROS-mediated signaling pathway. Anti-apoptotic effects.

HY-N3796

Echinulin Echinuline	NF-κB	Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Microorganisms
Echinulin (Echinuline) is a cyclic dipeptide carrying a triprenylated indole moiety. Echinulin contributes to the activation of T cell subsets, which leads to NF-κB activation.Echinulin exerts its immune roles by the NF-κB pathway.Echinulin has the potential to serve as a immunotherapeutic agent.

HY-119697

Setosusin (+)-Setosusin	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Other Diseases Source classification Microorganisms
Setosusin ((+)-Setosusin) is a fungal meroditerpenoid featuring a unique spiro-fused 3(2H)-furanone moiety.

HY-N1499

Nystose	Others	Saccharides Polysaccharides Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Rubiaceae Morinda officinalis How
Nystose is a tetrasaccharide with two fructose molecules linked via beta (1→2) bonds to the fructosyl moiety of sucrose.

HY-107824

D-Melibiose	Endogenous Metabolite	Saccharides Polysaccharides Structural Classification Malvaceae Endogenous metabolite Plants Malva sinensis Cav. Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
D-Melibiose is a disaccharide which is composed of one galactose and one glucose moiety in an alpha (1-6) glycosidic linkage.

HY-N11464

Kuwanon O	Others	Structural Classification Flavones Flavonoids Crassulaceae Crassula hemisphaerica Thunb. Plants Source classification
Kuwanon O is a flavonoid derivative with a fused dihydrochalcone partial moiety, that can be isolated from the root bark of Morus lhou (set.) Koidz.

HY-W067056

Methyl (E)-cinnamate Methyl (E)-3-phenylpropenoate	Others	Phenylpropanoids Simple Phenylpropanols Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants other families
Methyl (E)-cinnamate (EMC), a phytochemical constituent isolated from Alpinia katsumadai Hayata, is a natural flavor compound with anti-inflammatory properties. Methyl (E)-cinnamate is widely used in the food and commodity industry.

HY-121597

Yuankanin	Others	Structural Classification Flavones Flavonoids Thymelaeaceae Daphne genkwa Sieb. et Zucc. Plants Source classification
Yuankanin is a genkwanin-5-bioside, the sugar moiety being composed of xylose and glucose. Yuankanin can be isolated from the methanol extract of the aerial parts of Gnidia involucrata (Thymelaeaceae).

HY-N6681

15-Acetoxyscirpenol	Caspase Bacterial Apoptosis Antibiotic	Sesquiterpenes Terpenoids Infection Disease Research Fields Classification of Application Fields Source classification Microorganisms
15-acetoxyscirpenol, one of acetoxyscirpenol moiety mycotoxins (ASMs), strongly induces apoptosis and inhibits Jurkat T cell growth in a dose-dependent manner by activating other caspases independent of caspase-3.

HY-130993

Isatropolone A	Parasite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Infection Source classification Microorganisms
Isatropolone A, a natural product containing a 1,5-diketone moiety, is reisolated from Streptomyces Gö66. Isatropolone A shows potent activity against *Leishmania donovani* with an IC₅₀ of 0.5 μM.

HY-113123

LysoPC(14:0/0:0)	Endogenous Metabolite	Natural Products Source classification Endogenous metabolite
LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. LysoPC(14:0/0:0) has potent antispasmodic effect.

HY-N8171

Lagotisoide D 10-O-[(E)-3,4-Dimethoxycinnamoyl]-catalpol	Others	Terpenoids Iridoids Phenylpropanoids Simple Phenylpropanols Classification of Application Fields Disease Research Fields Other Diseases Source classification Plants Scrophulariaceae Lagotis yunnanensis W. W. Smith
Lagotisoide D is a lridoid glycoside from Lagotis yunnanensis.

HY-130994

Aeruginosin 865	NF-κB ADC Cytotoxin	Phenols Monophenols Natural Products Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Microorganisms
Aeruginosin 865, isolated from terrestrial cyanobacterium Nostoc sp. Lukešová 30/93, is the first aeruginosin-type peptide containing both a fatty acid and a carbohydrate moiety. Aeruginosin 865 inhibits translocation of NF-kB to the nucleus. Aeruginosin 865 has anti-inflammatory effect

HY-W018772

D-Ribose(mixture of isomers)	Endogenous Metabolite	Saccharides Structural Classification Endogenous metabolite Source classification Disease Research Fields Cancer Classification of Application Fields
D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner.

HY-W010970

5'-Guanylic acid disodium salt 5'-GMP disodium salt; 5'-guanosine monophosphate disodium salt	Endogenous Metabolite	Ketones, Aldehydes, Acids Other Diseases Disease Research Fields Classification of Application Fields Source classification Endogenous metabolite
5'-Guanylic acid disodium salt (5'-GMP disodium salt) is composed of guanine, ribose, and phosphate moieties and it is a nucleotide monomer in messenger RNA. Guanosine derivatives are involved in intracellular signal transduction and have been identified in repetitive genomic sequences in telomeres, in ribosomal DNA, immunoglobulin heavy‐chain switch regions, and in the control regions of proto-oncogenes.

HY-N10800

1,2,6,7,8,9-Hexahydro-1,6,6-trimethyl-3,11-dioxanaphth[2,1-e]azulene-10,12-dione	Others	Structural Classification Terpenoids Diterpenoids Labiatae Plants Hemistepta lyrata Source classification
1,2,6,7,8,9-Hexahydro-1,6,6-trimethyl-3,11-dioxanaphth[2,1-e]azulene-10,12-dione is a kind of chemical constituents of Salvia miltiorrhiza f. alba. The dihydroisotanshinone with a para-quinone moiety shows cytotoxicity and anti-tumor activity.

HY-N9448

Lacto-N-tetraose	Bacterial	Saccharides Polysaccharides Structural Classification Natural Products Endogenous metabolite Inflammation/Immunology Infection Disease Research Fields Classification of Application Fields
Lacto-N-tetraose is the significant core structure of human milk oligosaccharides (HMOs) naturally existing in human milk. Lacto-N-tetraose is consist of galactose, N-acetylglucosamine, and glucose moieties. Lacto-N-tetraose has prebiotic effect, immune regulatory effect, anti-inflammatory effects, intestinal cell responses regulatory effect, antibacterial activity and antiviral activity. Lacto-N-tetraose has been widely added to infant formula.

HY-N3513

Mulberrin Kuwanon C	Others	Flavonoids Flavones Phenols Polyphenols Classification of Application Fields Disease Research Fields Cardiovascular Disease Source classification Plants other families
Mulberrin is a strong inhibitor of organic anion-transporting polypeptide 2B1 (OATP2B1)-mediated estrone-3-sulfate (E3S) uptake with an IC₅₀ value being 1.8 ±1.5 μM.

HY-N10527

Isoglobotetraose Globoisotetraose	Others	Structural Classification Natural Products Microorganisms
Isoglobotetraose (Globoisotetraose) is the oligosaccharide moiety of human glycosphingolipids. Synthesis process: globotetraose (GalNAcβ1→3Galα1→4Galβ1→4Glc) and isoglobotetraose (GalNAcβ1→3Galα1→3Galβ1→4Glc).

HY-N10577

Chlorfortunone A	TGF-beta/Smad	Sesquiterpenes Terpenoids Structural Classification Chloranthus fortunei (A. Gray) Solms-Laub Plants Chloranthaceae
Chlorfortunone A is a novel sesquiterpenoid dimers, can be isolated from the roots of Chloranthus fortunei. Chlorfortunone A inhibits transforming growth factor (TGF)-β activity.

Species:	Human (15) Mouse (3)
Tag:	His (12) SUMO (1) Tag Free (2) Avi (3) GST (4) Fc (2)
Source:	HEK293 (6) Sf9 insect cells (3) P. pastoris (1) E. coli (8)

Cat. No.	Product Name	Species	Source

HY-P78030

RNF43 Protein, Mouse (HEK293, Fc)
E3 ubiquitin-protein ligase RNF43; RING finger protein 43; RING-type E3 ubiquitin transferase RNF43; Rnf43
Mouse HEK293
HY-P73485

XIAP Protein, Human (Avi)
E3 ubiquitin-protein ligase XIAP; ILP; IAP-3; XIAP; API3; BIRC4
Human E. coli
HY-P73537

XIAP Protein, Human (His)
E3 ubiquitin-protein ligase XIAP; ILP; IAP-3; XIAP; API3; BIRC4
Human E. coli
HY-P74343

CBLC Protein, Human (sf9, His-GST)
E3 ubiquitin-protein ligase CBL-C; CBLC; CBL3; RNF57
Human Sf9 insect cells
HY-P75894

ITCH/AIP4 Protein, Human (380a.a)
E3 ubiquitin-protein ligase Itchy homolog; AIP4; NAPP1; ITCH
Human E. coli
HY-P75970

Pellino-1 Protein, Human (sf9, His-GST)
E3 ubiquitin-protein ligase pellino homolog 1; PELI1; PRISM
Human Sf9 insect cells
HY-P77151

PPIL2 Protein, Human (His)
RING-type E3 ubiquitin-protein ligase PPIL2; CYC4; Cyp60; Rotamase PPIL2
Human E. coli
HY-P76007

RNF43 Protein, Human (HEK293, Fc)
E3 ubiquitin-protein ligase RNF43; RING finger protein 43; RNF43
Human HEK293
HY-P76008

RNF43 Protein, Human (HEK293, His)
E3 ubiquitin-protein ligase RNF43; RING finger protein 43; RNF43
Human HEK293

HY-P71570

TRIM21 Protein, Mouse (His-SUMO) Trim21; Ro52; Ssa1; E3 ubiquitin-protein ligase TRIM21; EC 2.3.2.27; 52kDa Ro protein; 52kDa ribonucleoprotein autoantigen Ro/SS-A; RING-type E3 ubiquitin transferase TRIM21; Ro(SS-A); Sjoegren syndrome type A antigen; SS-A; Tripartite motif-containing protein 21	Mouse	E. coli

HY-P77507

WWP2 Protein, Human (sf9, His-GST)
NEDD4-like E3 ubiquitin-protein ligase WWP2; Atrophin-1-interacting protein 2; AIP2; WWP2
Human Sf9 insect cells
HY-P78750

ZNRF3 Protein, Human (HEK293, His)
ZNRF3; Zinc; RING finger protein 3; RING-type E3 ubiquitin transferase ZNRF3; RING finger protein 203; KIAA1133; RNF203
Human HEK293

HY-P71340

STUB1 Protein, Human E3 Ubiquitin-Protein ligase CHIP; Antigen NY-CO-7; CLL-Associated Antigen KW-8; Carboxy Terminus of Hsp70-Interacting Protein; STIP1 Homology and U Box-Containing Protein 1; STUB1; CHIP	Human	E. coli

HY-P700593

MAP3K1 Protein, Mouse (His) MEKK; MEKK1; SRXY6; MEKK 1; MAPKKK1; MAP/ERK kinase kinase 1; MAPK/ERK kinase kinase 1; MEK kinase 1; mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase; mitogen-activated protein kinase kinase kinase 1	Mouse	E. coli

HY-P700392

UBAC1 Protein, Human (GST) UBAC1; UBA domain containing 1; UBADC1, ubiquitin associated domain containing 1; ubiquitin-associated domain-containing protein 1; GBDR1; UBA domain-containing protein 1; E3 ubiquitin-protein ligase subunit KPC2; ubiquitin associated domain containing 1; kip1 ubiquitination-promoting complex protein 2; glialblastoma cell differentiation-related protein 1; putative glialblastoma cell differentiation-related protein; UBADC1; RP11-432J22.3	Human	E. coli

HY-P700503

TRIM24 Protein, Human (P. pastoris, His) TRIM24; tripartite motif containing 24; TIF1, transcriptional intermediary factor 1 , tripartite motif containing 24; transcription intermediary factor 1-alpha; hTIF1; RNF82; TIF1A; Tif1a; TIF1-alpha; RING finger protein 82; tripartite motif-containing 24; E3 ubiquitin-protein ligase TRIM24; transcriptional intermediary factor 1; PTC6; TF1A; TIF1; TIF1ALPHA	Human	P. pastoris

HY-P77984

LILRA3/CD85e/ILT6 Protein, Human (HEK293, His-Avi)
CD85e; HM31; HM43; ILT6; ILT-6; LILRA3; LIR4; LIR-4HM43E3
Human HEK293
HY-P700776

LILRA3/CD85e/ILT6 Protein, Human (Biotinylated, HEK293, C-His-Avi)
CD85e; HM31; HM43; ILT6; ILT-6; LILRA3; LIR4; LIR-4HM43E3
Human HEK293

Cat. No.	Product Name

HY-10984S2

Pomalidomide-d4
Pomalidomide-d₄ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<

HY-10984S

Pomalidomide-d5
Pomalidomide-d₅ is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

HY-10984S1

Pomalidomide-d3
Pomalidomide-d₃ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors[1][2].

HY-14658S

Thalidomide D4
Thalidomide-d₄ is a deuterium labeled Thalidomide. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ~250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties[1][2].

HY-A0003S

Lenalidomide-d5

Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

HY-W018772S6

D-Ribose-d
D-Ribose-d is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gly

HY-W018772S1

D-Ribose-13C
D-Ribose-¹³C is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati

HY-W018772S

D-Ribose-18O
D-Ribose-¹⁸O is the ¹⁸O labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati

HY-107447S

N-Deshydroxyethyl Dasatinib-d8
N-Deshydroxyethyl Dasatinib-d₈ is the deuterium labeled N-Deshydroxyethyl Dasatinib. N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL[1].

HY-W018772S9

D-Ribose-d-3
D-Ribose-d-3 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g

HY-W018772S12

D-Ribose-d6
D-Ribose-d₆ is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl

HY-W018772S10

D-Ribose-d2
D-Ribose-d₂ is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl

HY-W018772S14

D-Ribose-d5
D-Ribose-d₅ is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl

HY-W018772S8

D-Ribose-d-2
D-Ribose-d-2 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g

HY-W018772S7

D-Ribose-d-1
D-Ribose-d-1 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g

HY-W018772S2

D-Ribose-13C-1
D-Ribose-¹³C-1 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-W018772S4

D-Ribose-13C-3
D-Ribose-¹³C-3 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-W018772S5

D-Ribose-13C-4
D-Ribose-¹³C-4 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-W018772S3

D-Ribose-13C-2
D-Ribose-¹³C-2 is the ¹³C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca

HY-W067056S1

Methyl(E)-cinnamate-d7
Methyl(E)-cinnamate-d₇ is the deuterium labeled Methyl (E)-cinnamate[1]. Methyl (E)-cinnamate (EMC), a phytochemical constituent isolated from Alpinia katsumadai Hayata, is a natural flavor compound with anti-inflammatory properties. Methyl (E)-cinnamate is widely used in the food and commodity industry[2].

HY-W067056S

Methyl (E)-cinnamate-d5
Methyl (E)-cinnamate-d₅ is the deuterium labeled Methyl (E)-cinnamate[1]. Methyl (E)-cinnamate (EMC), a phytochemical constituent isolated from Alpinia katsumadai Hayata, is a natural flavor compound with anti-inflammatory properties. Methyl (E)-cinnamate is widely used in the food and commodity industry[2].

HY-W018772S15

D-Ribose(mixture of isomers)-13c5

D-Ribose(mixture of isomers)-¹³C₅ isomers)-¹³C₅ is the ¹³C labeled D-Ribose(mixture of isomers)[1]. D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner[1].

Cat. No.	Product Name	Application	Reactivity

HY-P80919

TRAF6 Rabbit mAb TRAF6; RNF85; TNF receptor-associated factor 6; E3 ubiquitin-protein ligase TRAF6; Interleukin-1 signal transducer; RING finger protein 85	WB	Human, Rat
Rabbit Monoclonal Antibody to TRAF6

HY-P80730

KAP1 (YP7016) Mouse mAb TRIM28; KAP1; RNF96; TIF1B; Transcription intermediary factor 1-beta; TIF1-beta; E3 SUMO-protein ligase TRIM28; KRAB-associated protein 1; KAP-1; KRAB-interacting protein 1; KRIP-1; Nuclear corepressor KAP-1; RING finger protein 96; Tripart	WB, IHC-F, IHC-P, ICC/IF, IP	Human
Mouse Monoclonal Antibody to KAP1

E3 ligase-recruiting Moiety

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products